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SUMMARY 
The mammalian intestinal tract is a complex ecosystem colonised by a high and diverse 
number of commensal bacterial. Bacteria colonising the intestinal tract have a profound 
impact on host health e.g. by acting as a barrier against colonisation by pathogens and by 
contributing to digestion of complex food components. In this regard there is a considerable 
interest in dietary components that can modulate the gut microbiota and potentially improve 
gut health.  
Some gut bacteria, known as probiotics, are belived to improve gut health upond ingestion, 
whereas non-digestible (ND) dietary carbohydrates, known as prebiotics, are food 
components aimed at selectively stimulating such beneficial bacteria already colonizing the 
intestinal tract. In this regard, prebiotics and other ND dietary carbohydrates may improve 
host resistance to intestinal infections by selectively modulating the composition of the gut 
microbiota or by stimulating the immune response. 
Salmonella is a genus of Gram-negative bacteria that are a major cause of food-borne illness 
globally. Several studies with probiotics have demonstrated protective effects against murine 
Salmonella infections, while studies with prebiotics have shown conflicting results. Therefore 
the aim of the present thesis was to investigate the effect of selected ND dietary carbohydrates 
on the large intestinal microbiota and susceptibility to Salmonella enterica serovar 
Typhimurium SL1344 infection in mice.  
The thesis contains an introduction to the digestive function of the gastrointestinal tract and 
the associated microbiota, followed by a description of dietary strategies for modulation of the 
intestinal microbiota with particular emphasis on effects on Salmonella infections. 
Subsequently, three manuscripts are presented based on the experimental studies performed.  
Results presented in Manuscript I demonstrated no in vivo protective effect of the investigated 
carbohydrates against the Salmonella infection. In contrast, two of the investigated substrates 
(fructo-oligosaccharides and xylo-oligosaccharides) demonstrated an adverse rather than a 
protective effect against the infection.  
Manuscript II investigated diet-induced changes in the large intestinal microbiota of mice 
exhibiting a reduced resistance to the Salmonella infection. Diets supplemented with fructo-
oligosaccharides or xylo-oligosaccharides induced a number of microbial changes in the 
faecal microbiota including an increase in the Bacteroidetes phylum, the Bacteroides fragilis 
group and in Bifidobacterium spp., while reductions were observed in the Firmicutes phylum 
and the Clostridium coccoides group. The findings thus suggest that some microbial changes 
in the large intestine may increase the infectious potential of Salmonella. 
The last study, presented in Manuscript III, was performed during a research stay at CSIRO 
Food and Nutritional Sciences, Australia. In this study a two-stage continuous fermenter was 
used to determine if incubating human faeces with xylo-oligosaccharides (XOS) lowers faecal 
water genotoxicity induced by protein fermentation. XOS fermentation was seen to reduce 
faecal water genotoxicity in vessel 1, but to increase the genotoxicity in vessel 2. Butyrate 
concentrations were significantly elevated in both vessels and could be related to an increase 
in the C. coccoides group. Other microbial changes observed, including a reduction in 
Bifidobacterium spp. and sulphate-reducing bacteria, suggest that quantities of some bacterial 
species are related to changes in faecal water genotoxicity.  
Conclusively, the studies contribute to our knowledge of the effect of some ND dietary 
carbohydrates on the composition of the large intestinal microbiota and the effect such 
changes may have on the susceptibility to Salmonella infections or the risk of developing 
colon cancer. 
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SAMMENDRAG (DANISH SUMMARY) 
Tarmkanalen hos pattedyr er et komplekst økosystem koloniseret af et højt og mangfoldigt 
antal naturligt forekommende bakterier. Bakterier, der koloniserer tarmkanalen har en 
afgørende betydning for værtens helbred f.eks. ved at fungere som en barriere mod 
kolonisering af patogene bakterier og ved at bidrage til fordøjelse af komplekse 
fødevarekomponenter. I denne forbindelse er der en betydelig interesse for 
fødevareingredienser, der kan ændre på sammensætningen af tarmmikrobiota og potentielt 
forbedre tarmmiljøet.  
Indtagelse af nogle tarmbakterier, såkaldte probiotika, menes at have en gunstig effekt på 
tarmmiljøet, mens ufordøjelige kulhydrater, såkaldte præbiotika, er fødevareingredienser 
udviklet specielt til selektivt at stimulere sådanne gavnlige bakterie, som findes naturligt i 
tarmen. Præbiotika og andre ufordøjelige kulhydrater i kosten menes således at kunne 
reducere værtens modtagelighed for tarminfektioner ved selektivt at ændre på 
sammensætningen af tarmens mikrobiota eller ved at stimulere immunforsvaret. 
Salmonella er en slægt af Gram-negative bakterier, der på verdensplan udgør en væsentlig 
årsag til fødevarerelaterede sygdomsudbrud. Flere studier har vist en forebyggende effekt af 
probiotika mod murine Salmonella infektioner, mens studier med præbiotika har vist 
modstridende resultater. Formålet med nærværende afhandling var således at undersøge 
effekter af udvalgte ufordøjelige kulhydrater på mikrobiotaen i tyktarmen og på 
modtageligheden for Salmonella enterica serovar Typhimurium SL1344 infektioner hos mus. 
Afhandlingen omfatter en introduktion til mave-tarmkanalens fordøjelsesfunktion og den 
tilhørende mikrobiota. Efterfølgende gives en beskrivelse af kost-strategier udviklet med 
henblik på at ændre på sammensætningen af tarmmikrobiotaen med særligt fokus på studier 
omhandlende effekter på Salmonella infektioner. Afslutningsvist præsenteres resultaterne af 
de gennemførte eksperimentelle studier i tre manuskripter. 
Resultater af fodringsforsøg med ufordøjelige kulhydrater (Manuskript I) viste ingen in vivo 
forebyggelse af Salmonella infektionen. Derimod resulterede fodring med to af de testede 
kulhydrater (frukto-oligosakkarider og xylo-oligosakkharider) i en øget modtagelighed for 
infektionen. Effekter af disse kulhydrater på sammensætningen af tarmmikrobiotaen blev 
undersøgt i Manuskript II. Foder indeholdende frukto-oligosakkarider eller xylo-
oligosakkharider medførte en række ændringer i mikrobiotaen i fæces, herunder en stigning i 
Bacteroidetes, Bacteroides fragilis gruppen og i Bifidobacterium spp. samt en reduktion i 
Firmicutes og Clostridium coccoides gruppen. Resultaterne antyder således, at visse 
bakterielle ændringer i tyktarmens mikrobiota kan øge Salmonellas’ infektionspotentiale. 
Det sidste studie (Manuskript III) blev gennemført under forskningsopholdet ved CSIRO 
Food and Nutritional Sciences, Australien. Studiet omfattede anvendelsen af et to-trins 
fermenteringssystem til undersøgelse af, om xylo-oligosakkharider (XOS) ved inkubering 
med humant fæces kan reducere det genotoksiske potentiale af fækalt vand induceret af 
protein fermentering. XOS fermentering blev vist at reducere genotoksiciteten i den første 
fermentor, mens studiet viste en øget genotoksitet for den efterfølgende fermentor. 
Koncentrationen af butyrat var signifikant forøget i begge fermentorer og kunne relateres til 
en øget forekomst af C. coccoides gruppen. Andre ændringer i den bakterielle population, 
herunder en reduktion i Bifidobacterium spp. og sulfat-reducerende bakterier antydede, at 
forekomsten af visse bakteriearter kan relateres til ændringer i genotoksiteten af fækalt vand.  
Samlet set, bidrager de gennemførte studier til viden om effekter af indtagelse af visse 
ufordøjelige kulhydrater på sammensætningen af mikrobiotaen i tyktarmen og hvilke 
konsekvenser dette kan have for modtageligheden for Salmonella infektioner eller risikoen for 
at udvikle tyktarmskræft. 
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ABBREVIATIONS 
AGA Apiogalacturonan 
aps Adenosine-5-phosphosulfate reductase gene 
ATP Adenosine triphosphate  
CFU Colony forming units 
CSIRO Commonwealth Scientific and Industrial Research Organisation 
DGGE Denaturing Gradient Gel Electrophoresis 
dsr Dissimilatory sulfite reductase gene 
DP Degree of polymerization 
EPEC Enteropathogenic E. coli  
FAE Follicle associated epithelium 
FOS Fructo-oligosaccharide 
GalpA Galacturonic acid 
GI Gastrointestinal 
GOS Galacto-oligosaccharide 
Hb Haemoglobin 
HG Homogalacturonan 
IBD Inflammatory bowel diseases 
Ig Immunoglobulin 
LPF Long polar fimbria  
MLN Mesenteric lymph nodes 
NK cell Natural killer cell 
NKT cell Natural kille T cell 
ND Non-digestible 
PDX Polydextrose 
p.i. Post-infection 
RG Rhamnogalacturonan 
RNI Reactive nitrogen intermediate 
ROS Reactive oxygen specie  
RS Resistant starch 
SCFA Short chain fatty acid 
SCV Salmonella containing vacuole 
SD Standard deviation 
SEM Standard error of the mean 
S. Enteritidis S. enterica serovar Enteritidis  
S. Paratyphi S. enterica serovar Paratyphi 
SPI Salmonella pathogenicity island 
SRB Sulphate-reducing bacteria 
S. Typhi S. enterica serovar Typhi 
S. Typhimurium S. enterica serovar Typhimurium  
T3SS Type-III-secretion-system 
Th cell T-helper cell 
TOS Transgalactosylated oligosaccharide 
XGA Xylogalacturonan 
XOS Xylo-oligosaccharide 
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1. THE HUMAN GASTROINTESTINAL SYSTEM AND THE ASSOCIATED MICROBIOTA 
Digestion of food and absorption of nutrients is a complex process performed by the 
gastrointestinal (GI) system (Figure 1). The system is composed of the GI tract, the saliva 
glands, the liver (producing bile), the gall bladder (stores and secretes bile) and the pancreas. 
The GI tract extents from the mouth to the anus covering the oral cavity, the esophagus, the 
stomach, the small intestine (the duodenum, the jejunum and the ileum), the cecum and the 
colon (the ascending colon, transverse colon, descending colon and sigmoid rectum) [1].  
 
 
Figure 1. The human gastrointestinal system [1].  
 
Microorganisms colonizing the intestinal tract have a profound impact on human health e.g. 
by acting as a barrier against pathogens and by contributing to degradation of complex food 
components resulting in the release of energy sources important for host health (e.g. short 
chain fatty acids) [2]. Some gut bacteria can be used to improve gut health. Probiotics (section 
3.1) are microorganisms (most commonly bacteria of the genera Lactobacillus and 
Bifidobacterium) that upon ingestion exert beneficial effects on gut health, whereas non-
digestible (ND) dietary carbohydrates known as prebiotics (section 3.2) are food components 
aimed at selectively stimulating beneficial bacteria already colonizing the intestinal tract [3].  
The following section gives an introduction to the human digestive system and the associated 
microbiota. Subsequently, dietary strategies for modulation of the intestinal microbiota and 
possible benefits for host health are described with particular emphasis on effects on 
Salmonella infections.    
1.1 THE DIGESTIVE FUNCTION OF THE GASTROINTESTINAL SYSTEM 
The mechanical and enzymatic digestion of food starts in the mouth, where saliva acts as a 
solvent for solid foods. The secretion from the salivary glands contains enzymes, primarily α-
amylase and lower amounts of lipase and ribonuclease that contribute to the initial hydrolysis 
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of the ingested food. Furthermore, saliva contains lysozyme with antibacterial activity and 
immunoglobulin A (IgA) that protects against food-borne antigens. From the mouth the 
moistened and partly hydrolysed food is passed on to the stomach through the oesophagus 
[1,4]. In the stomach the food is mixed with gastric juice producing the so-called chyme [4]. 
The low pH of the gastric juice kills most microorganisms and is an important defence 
mechanism against pathogens [5].  
From the stomach the chyme is released into the upper part of the small intestine, the 
duodenum. The rate of chyme released depends on the composition of the processed food. 
Food with a high content of carbohydrates is released faster than protein-rich food, followed 
by release of chyme produced from a meal high in fat [1].  
The small intestine is the part of the gastrointestinal tract, where most of the digestion and 
absorption of nutrients take place. The epithelial cells lining the small intestine contribute to 
the production of digestive enzymes and have a large surface area due to the presence of villi 
and microvilli [1]. In response to chyme passing into the duodenum, bile and pancreatic juice 
are secreted into the duodenal lumen. Bile is an alkaline solution containing bile acids, bile 
pigments and traces of cholesterol, fatty acids and phospholipids [1,4]. Bile acids are 
synthesized by the liver from cholesterol and are essential for digestion and absorption of 
dietary fat, cholesterol and fat-soluble vitamins [6,7].  
The pancreatic secretion includes an electrolytic and an enzymatic secretion. The electrolytic 
secretion is alkaline with a pH of 7.5-9 and acts as a buffer of the acidic chyme making the 
pH optimal for the activity of the digestive enzymes in the enzymatic secretion. The 
enzymatic secretion contains a variety of enzymes for digestion of proteins (trypsin, 
chymotrypsin, carboxypeptidase and elastase), lipids (lipase, phospholipase, esterase), nucleic 
acids (ribonuclease, deoxyribonuclease) and carbohydrates (α-amylase) [1,8].  
The pancreatic α-amylase has a higher activity compared to salivary α-amylase and the 
highest concentration of the enzyme is found in the duodenum. After entering the duodenum 
the majority of ingested starch is quickly hydrolysed to maltose, malto-oligosaccharides and 
α-limit dextrins by pancreatic α-amylase. Di- and oligosaccharides are further digested by 
enzymes produced by the epithelial cells of the duodenum and jejunum followed by 
absorption of monosaccharides. The most important enzymes are lactase (hydrolyses lactose), 
sucrase (hydrolyses sucrose), α-dextrinase (debranches α-limit dextrins) and glucoamylase 
(hydrolyses malto-oligosaccharides) [8].  
Among polysaccharides, starch is the only one that is hydrolysed by digestive enzymes in the 
small intestine, since they are only capable of hydrolysing α-glycosidic linkages with the 
exception of lactase hydrolysing ß-bindings in lactose [1,9]. However, in the form of resistant 
starch (RS) parts of ingested starch can reach the colon undigested. Four major type of RS 
have been classified with RS1 being physically inaccessible to digestion e.g. due to intact cells 
walls in grains and seeds, RS2 comprises granular starch in e.g. potatoes, RS3 is retrograded 
starch produced by cooking and cooling of starchy foods and RS4 comprises chemically 
modified starch [10].  
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Oligo- and polysaccharides with ß-glycosidic linkages e.g. cellulose are not hydrolysed and 
pass the small intestine undigested [8]. Carbohydrates that resist digestion reach the colon 
chemically intact, where the digestive process is continued through bacterial fermentation [1]. 
The carbohydrates provide energy for bacterial growth with fermentation resulting in 
production of hydrogen, carbon dioxide and short chain fatty acids (SCFA) [4]. SCFAs 
function as the primary energy source for the colonic epithelium and are discussed further in 
section 2.1.   
Dietary proteins are digested partly by pepsin in the stomach and partly by proteases secreted 
by the pancreas (trypsin, chymotrypsin, carboxypeptidase and elastase). These enzymes 
reduce the proteins to smaller peptides, that are further digested into amino acids and di-, tri- 
and tetra-peptides by membrane integrated peptidases produced by the epithelial cells of the 
duodenum and jejunum. The amino acids and small peptides are absorbed followed by 
hydrolysis of the peptides by cytosolic peptidases and release of the amino acids to the blood 
[1,8]. 
Digestion of dietary fats is a complex process involving emulsification and micelle formation 
[1]. The primary dietary lipids are triglycerids, which are emulsified in the small intestine 
with the help of bile acids. This produces emulsion droplets allowing the access of water-
soluble lipolytic enzymes produced by the pancreas [8]. The digestion products (free fatty 
acids and mono-glycerides) need to form micelles in order to reach the epithelial surface [4]. 
Due to their amphipathic structure (hydrophilic and hydrophobic) bile acids are capable of 
forming micelles and to carry lipids to the surface of the epithelium. Here, the micelles 
disrupt and the lipids diffuse into the epithelial cells [4].  
Throughout the digestive tract water is absorbed and the digestive process is terminated with 
undigested and non-fermented food residues, bacterial biomass, exfoliated cells and mucus 
stored in the rectum and finally excreted as faeces [1]. The time it takes a substance to travel 
through the entire gastrointestinal tract (the transit time) is on average 24-72 hours. Most of 
the time (18-64 hours) is in the colon, with the time in the stomach and small intestine only 
accounting for 4-8 hours [4].  
1.2 COMPOSITION OF THE HUMAN GASTROINTESTINAL MICROBIOTA 
The human gastrointestinal microbiota is a complex ecosystem containing all three domains 
of life: Bacteria, archaea, and eukarya [11]. Archaea and Eukarya only represent a single 
phylum each, whereas the composition of the bacterial microbiota is very diverse [12].  
The intestinal microbiota is established shortly after birth with the mode of delivery (vaginal 
or caesarean) and the type of feeding (breast milk or infant formula) affecting the composition 
of bacteria initially colonising the gut. Faecal samples from infants delivered by caesarean 
section have been reported to contain lower numbers of bifidobacteria and bacteroides, but 
higher numbers of clostridia compared to vaginally delivered infants [13]. In addition, breast-
fed and formula-fed infants have different microbiotas. Breast-fed infants are usually 
colonised by high numbers of bifidobacteria, whereas high numbers of bacteroides and 
clostridia colonise the intestinal tract of formula-fed infants compared to breast-fed [14,15]. 
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The intestinal microbiota of children stabilizes at weaning and is comparable to the adult 
microbiota at around 2 years of age [4].  
Several studies have attempted to describe the bacterial community of the intestinal tract in 
adult humans. Initially such studies were based on cultivation dependent methods, but more 
recent studies have include cultivation independent molecular methods based on analysis of 
16S ribosomal DNA (rDNA) sequences [16]. Since molecular methods indicate that 60-80% 
of the human intestinal microbiota have not been cultivated [17], such methods have 
improved the ability to gain insight in the composition of the microbial community.  
The current knowledge of the composition of the human gut microbiota has recently been 
reviewed. A total of nine bacterial phyla have been identified with the most dominating being 
the Firmicutes, Bacteroidetes and Actinobacteria followed by Proteobacteria (Figure 2) [12]. 
In a study by Eckburg et al. [18] investigating the composition of the human faecal 
microbiota, based on sequence analysis of 16S rDNA, seven bacterial phyla (Firmicutes, 
Bacteroidetes, Proteobacteria, Actinobacteria, Verrucobacteria, Fusobacteria and one 
unclassified phyla) were identified, as well as one archaeal phylotype. The dominating phyla 
were the Firmicutes (51% of the total bacterial sequences) and Bacteroidetes (48%). Among 
the Firmicutes 95% of the sequences belonged to the genera Clostridium with the majority 
belonging to the butyrate-producing cluster XIVa [18].  
  
 
Figure 2. 16S rDNA-based phylogenetic tree of the microbial community present in the human intestinal tract. 
Differences in darkness indicate phylogenic groups corresponding to phylotypes detected in cultivation based 
studies (white) or in cultivation-independent studies (black). Numbers indicate distinct phylotypes within each 
group [12].  
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At genus level, based on cultivation dependent analysis of faecal samples, the microbiota is 
dominated by the genera Bacteroides (the Bacteroides phylum), Clostridium, Eubacterium, 
Peptococcus, Peptostreptococcus, Ruminococcus (the Firmicutes phylum) and 
Bifidobacterium (Actinobacteria). Sub-dominating genera are Enterococcus and 
Lactobacillus, Escherichia, Enterobacter, Klebsiella and Proteus [3].  
Both the diversity and number of bacteria present varies according to the location in the GI 
tract (Figure 3) [19]. The total bacterial cell number has been estimated as 10
14
, with numbers 
as high as 10
12
 cells/g recorded for the colon. Lower numbers are found in the stomach and 
duodenum (<10
3
 cells/ml) and in the jejunum and ileum (10
4
-10
6
 cells/ml) [19,20]. Only few 
bacterial species can survive the acidic conditions in the stomach with Heliobacter pylori 
being the most well known “stomach bacterium” [5]. Other genera detected in the stomach 
and duodenum are lactobacilli and streptococci [4,19]. From the duodenum through the 
jejunum and ileum the bacterial diversity increases, as indicated by figure 3, with the most 
complex bacterial community present in the colon [19]. 
 
                                         
Figure 3. Microbial numbers and diversity throughout the human gastrointestinal tract [19]. 
1.2.1 THE HUMAN VERSUS THE MOUSE INTESTINAL MICROBIOTA 
In the present thesis the effects of dietary interventions were studied using mice. Even though 
mice are an often used model in the study of dietary effects on the intestinal microbiota, the 
composition of the mouse gut microbiota have not been studied as intensively as for humans. 
Still, a considerable similarity between the mouse and human gut microbiota have been 
reported by Ley et al. [21] based on analysis of caecal 16S rDNA sequences from mice. Ley 
and co-workers found that the dominating phyla in mice were the Firmicutes and 
Bacteroidetes as reported for humans [18]. Firmicutes accounted for ~60% of a total of 5.088 
sequences isolated from lean C57BL/6J mice and Bacteroidetes for ~40%. More than 75% of 
the Firmicutes belonged in the Clostridium cluster XIVa also reported as a dominating cluster 
in humans [18].  
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2. FERMENTATION OF NON-DIGESTIBLE DIETARY CARBOHYDRATES  
Non-digestible (ND) dietary carbohydrates, that escape digestion in the small intestine, 
become available as growth substrates for the colonic microbiota. In humans, the majority of 
ND dietary carbohydrates that reach the colon are plant cell wall polysaccharides (e.g. 
cellulose, arabinoxylan, xyloglucan, ß-glucan, mannan, pectins and lignin) and resistant starch 
[22,23]. In addition, commercial products of ND dietary carbohydrates known as prebiotics 
e.g. inulin and fructo-oligosaccharides are also consumed as a way of selectively 
manipulating the composition of the gut microbiota [24].  
Degradation of undigested carbohydrates in the colon initially involves bacterial groups 
capable of degrading complex polysaccharides [23]. In humans, bacterial species capable of 
degrading dietary fibres (e.g. cellulose, inulin and xylan) have been identified within the 
genera Bacteroides, Roseburia, Ruminococcus and Bifidobacterium [23,25-29]. Since 
Bacteroides is one of the numerically dominating bacterial genera in the human large intestine 
[30], they are likely to play a central role in degradation of complex carbohydrates entering 
the colon. This has been confirmed by the capability of Bacteroides spp. to utilizing a variety 
of plant polysaccharides [31]. In addition, a large proportion of the genome of B. 
thetaiotaomicron encodes genes involved in harvesting and metabolizing polysaccharides 
[32]. According to Xu et al. [32] the representation of glycosylhydrolases (e.g. α- and ß-
galactosidases, α- and ß-glucosidases, ß-glucuronidases, ß-fructofuranosidases, α-
mannosidases, amylases and xylanases) in the genome of B. thetaiotaomicron exceeds that of 
any other sequenced bacteria. 
Hydrolysis of polysaccharides into smaller fragments (oligosaccharides) makes the substrates 
available for fermentation by other members of the bacterial community [33]. Non-digestible 
oligosaccharides such as fructo-oligosaccharides (FOS) and inulin (a mixture of oligo- and 
polysaccharides) occur naturally in a variety of vegetables and fruits as a source of 
carbohydrate storage [1] and are used to selectively stimulate the growth of bifidobacteria in 
the human large intestine [24]. The ability of bifidobacteria to ferment FOS has been ascribed 
to the activity of β-fructofuranosidases identified in several bifidobacterial species including 
B. lactis [34], B. breve [35], B. infantis [36] and B. longum [37]. The genome of B. longum 
has been fully sequenced and was found to dedicate more than 8% of the genome to 
metabolism of oligosaccharides. Besides encoding many enzymes for fermentation of mono- 
and disaccharides, the genome encoded a β-fructofuranosidase as well as proteins with 
homology towards xylanases, arabinosidases, α-galactosidases, β-galactosidases, β-
glucosidases and hexoaminidases. Based on these findings B. longum is capable of fermenting 
a wide selection of carbohydrates. In addition, eight high-affinity oligosaccharide transporters 
were identified likely to provide B. longum with a competitive advantage in the uptake of 
oligosaccharides [37].    
Studies on the activity of the β-fructofuranosidases (all intracellular) encoded by B. lactis, B. 
breve and B. infantis demonstrated that the affinity of the enzyme may vary between species 
and that the ability to cleave β-1.2 bounds in inulin and FOS is affected by the complexity of 
the substrate. In B. lactis the strongest affinity was observed for terminal β-1.2 bounds 
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between fructose units, while β-fructofuranosidases produced by B. breve only cleaved β-1.2 
glucose-fructose links. In all three species a high activity was recorded towards degradation of 
FOS, whereas only low activities were recorded towards inulin [34-36]. Differences in the 
enzyme activity towards FOS and inulin are in agreement with results from the in vitro 
fermentation studies by Rossi et al. [29] investigating the relationship between chain length of 
fructans (inulin and FOS) and the ability of bifidobacteria to ferment them. In this study only 
few bifidobacterial strains (8 of 55) were capable of fermenting inulin and the fermentation 
was related to production of extracellular β-fructofuranosidases.  
2.1 SHORT CHAIN FATTY ACIDS 
The major end-products of bacterial fermentation of dietary carbohydrates are short chain 
fatty acids (SCFA) and gasses including H2, CO2 and CH4 [30]. The primary SCFAs produced 
in the human large intestine are acetate, propionate and butyrate with the majority of SCFAs 
absorbed in the colon and excretion of only 5-10% in faeces [38]. In humans, the total SCFA 
concentration in the proximal colon is ~70-140 mM depending on diets and decreases to ~20-
70 mM in the distal colon [10]. The faecal molar ratio (%) of the three dominating SCFAs is 
approximately 60:20:20 (acetate:propionate:butyrate), although the ratio may be affected by 
dietary changes [10,38]. From in vitro studies, simulating the conditions in the human colon, 
the molar ratio (%) of the three acids have been recorded as 60-80 for acetate, 14-22 for 
propionate and 8-23 for butyrate [39].  
SCFAs are produced within the bacterial cells from monosaccharides generated from the 
breakdown of oligo- and polysaccharides. In the cells metabolism of monosaccharides result 
in the release of SCFAs along with a net production of 4 adenosine triphosphate (ATP) 
molecules [40]. All three SCFAs are rapidly absorbed by host tissue and are primarily 
metabolized by the gut epithelium, liver and muscles [39].  
Acetate is absorbed by the gut epithelium, passes through the liver via portal blood to 
peripheral tissues, where it provides energy to muscles (e.g. skeletal and cardiac muscles and 
the brain) [39,41]. 
Propionate is transported to the liver through the portal vein and is an important precursor for 
gluconeogenesis in ruminants [40]. In humans, the role of propionate metabolism is less clear, 
but it is suggested to be involved in the cholesterol lowering effect of dietary fibres [42]. In 
rats, studies on the effect of propionate on cholesterol metabolism have demonstrated reduced 
cholesterol levels in the liver and blood [43-45]. In a study with human volunteers serum 
propionate was negatively correlated to total serum cholesterol in men but not in women [46], 
whereas other studies have reported no effect of propionate on serum cholesterol levels in 
humans [47-49].  
Of the three SCFAs most studies have dealt with the effect of butyrate on colonic health. 
Besides being the preferred energy sources for colonic epithelial cells [50], butyrate functions 
as a signalling molecule involved in cell cycle arrest and induction of apoptosis in cancer cells 
[10,51-53] and has been implicated in protection against colon cancer [54-56]. Furthermore, 
butyrate may reduce the infectious potential of Salmonella. In a study by Van Immerseel et al. 
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[57] pretreatment of S. enterica serovar Enteritidis (S. Enteritidis) with butyrate significantly 
reduced pathogen invasion of chicken caecal epithelial cells in vitro and feed supplemented 
with butyrate reduced numbers of the pathogen in the ceaca of chickens [58]. A reduced 
invasion of epithelial cells after exposure to butyrate may be explained by a down-regulation 
of expression of genes important for Salmonella invasion as demonstrated by Gantois et al. 
[59]. Growth of S. Enteritidis and S. enterica serovar Typhimurium (S. Typhimurium) in 
media supplemented with butyrate was seen to reduce invasion of HeLa cells for both 
serovars and to down-regulate expression of invasion-associated genes encoded by the  
Salmonella pathogenicity island (SPI-1) (described further in section 4.1) [59].  
 
Degradation of dietary fibres in the large intestine is a complex metabolic pathway involving 
several bacterial species and creates the opportunity for cross-feeding. This may in turn affect 
the release of metabolic end-products such as SCFAs (Figure 4) [60]. Differences in SCFA 
production may also be a reflection of different dietary carbohydrates yielding different 
amounts and types of SCFAs [41]. Starch fermentation generally yield high ratios of butyrate, 
whereas pectin is a poor source of butyrate [41,61]. In contrast, pectin is a good source of 
acetate production [41]. Hence, by feeding different fiber sources it is possible to manipulate 
the types and amounts of SCFAs produced [62]. 
 
 
 
Figure 4. Schematic presentation of cross-feeding in relation to microbial degradation of complex carbohydrates 
in the large intestine [60]. 
 
Examples of cross-feeding affecting the production of SCFAs have been demonstrated in 
vitro. Co-culture of butyrate-producing strains of Eubacterium, Anaerostipes (both lactate-
utilizers) and Roseburia with Bifidobacterium adolescentis demonstrated two routes of 
metabolic cross-feeding [63]. All three butyrate-producing strains were unable to ferment the 
growth substrates (starch and FOS) in mono-cultures but produced butyrate in co-culture with 
B. adolescentis. Hence, the results indicate cross-feeding of either lactate produced by B. 
adolescentis (Eubacterium and Anaerostipes) or of partially degraded carbohydrates released 
by B. adolescentis (Roseburia) [63].  
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The occurrence of cross-feeding between strains of bifidobacteria has also been suggested. In 
the in vitro study by Rossi et al. [29] only few strains of bifidobacteria were capable of 
fermenting inulin in mono-cultures. However, no difference in the growth of bifidobacteria on 
FOS and inulin were observed in faecal cultures. The results thus suggest, that stimulation of 
bifidobacteria in mixed cultures and in vivo may partly be explained by cross-feeding of 
oligosaccharides released by inulin-degrading strains, demonstrating the nutritional 
dependence among bacteria colonizing the large intestine [29,60].  
3. DIETARY STRATEGIES FOR MODULATING THE INTESTINAL MICROBIOTA 
Some intestinal bacteria are regarded as beneficial for gut health [64]. In general, the gut 
microbiota have been divided into genera of either potentially harmful/pathogenic or 
potentially health promoting bacteria [30,64]. The genera Bifidobacterium and Lactobacillus 
do not contain any known pathogens [64] and are classified as potentially health promoting 
with positive effects on 1) inhibition of growth of harmful bacteria, 2) stimulation of immune 
functions, 3) digestion and absorption of food ingredients/minerals and 4) synthesis of 
vitamins [30]. At least three strategies exist within modulation of the gut microbiota. 
Probiotics are the concept of consuming microorganisms with known beneficial effects on gut 
health [65], prebiotics are non-digestible dietary carbohydrates claimed to be specifically 
fermented by beneficial gut bacteria [30] and finally, synbiotics are a combination of pro- and 
prebiotics with the idea, that probiotics travel to the colon, while prebiotics support their 
growth combined with a stimulation of already present beneficial bacteria [16].   
3.1 PROBIOTICS 
The concept of probiotics was initially defined by Fuller [65] as ”a live microbial feed 
supplement that beneficially affects the host animal by improving its intestinal microbial 
balance”. In order to do so probiotics need to fulfil four criteria: 1) probiotics must be capable 
of being prepared in a viable manner and in large scale, 2) probiotics need to remain viable 
and stable during storage and use, 3) probiotics should be able to survive the conditions in the 
intestinal tract and 4) the host should gain beneficially from ingesting the probiotics [30]. 
More recently probiotics have been defined by Salminen et al. [66] as “ microbial cell 
preparations or components of microbial cells that have a beneficial effect on the health and 
well-being of the host”. According to this definition probiotics do not need to be viable.  
Probiotics have traditionally been used for years in the production of fermented food products 
such as yoghurt due to their production of lactic acid [16]. Several bacterial genera have been 
used as probiotics (lactobacilli, streptococci, enterococci, lactococci, bifidobacteria and 
bacillus), but also fungi such as Aspergillus spp. and Saccharomyces spp. have been used. 
Still, the most frequently used probiotics are species of the genera Lactobacillus and 
Bifidobacterium (e.g. Lactobacillus acidophilus, L. casei, L. rhamnosus, L. reuteri, L. 
plantarum and L. johnsonii and Bifidobacterium bifidum, B. lactis, B. longum B. infantis and 
B. breve) [4,30].  
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A considerable number of benefits for human health have been postulated to result from the 
intake of probiotics. These include 1) prevention of diarrheal illnesses, 2) prevention of 
common infections (e.g. colds and fever), 3) prevention of allergic disorders, 4) prevention of 
inflammatory bowel disease and 5) prevention of colon cancer (Table 1). Furthermore, 
protection against pathogenic infections has been investigated in vitro [67-71] and in vivo [72-
85] using animal models, including studies on prevention of Salmonella infections [78-85].  
 
Table 1. Potential health benefits of probiotic consumption studied in humans 
Effect References 
Prevention of diarrheal illnesses [86-89] 
Prevention of common infections (e.g. colds and fever)  [88,90-93] 
Prevention of allergic disorders [94-99] 
Prevention of inflammatory bowel disease [100-104] 
Prevention of colon cancer  [105,106] 
3.1.1 ANTAGONISTIC EFFECTS OF PROBIOTICS 
One way by which probiotics may contribute to gut health is by improving the colonization 
resistance [107], being the mechanism whereby the intestinal microbiota limits colonization 
of exogenous and potentially pathogenic microorganisms [108]. Several factors may 
contribute to an improved colonization resistance, with one being the release of acidic 
metabolic end-products such as lactic acid and other SCFAs that lower the gut pH to levels 
below those optimal for growth and competition by the pathogen. Other factors contributing 
to the colonization resistance are competitive exclusion of adherence of the pathogen, 
competition for nutrients, production of antimicrobial substances and immune modulation 
[107]. For a detailed review on the antagonistic activities of Lactobacillus and 
Bifidobacterium the reader is referred to the review by Servin [109], with some examples 
given below.  
Competitive exclusion of pathogen adherence in vitro by 12 commercial probiotic strains has 
been investigated by Collado et al. [71]. All probiotic strains were able to inhibit and displace 
adhesion of Bacteroides vulgatus, Clostridium histolyticum, Clostridium difficile, 
Staphylococcus aureus and Enterobacter aerogens, but most could not inhibit adhesion of 
Escherichia coli (12/12), Listeria monocytogenes (7/12) and S. Typhimurium (9/12) as well as 
displace adhesion of E. coli (12/12) and S. Typhimurium (7/12). By competitive exclusion 
adhesion of four pathogens cold be inhibited by nearly all probiotics (C. difficile (12/12), S. 
aureus (12/12), E. aerogens (12/12) and B. vulgatus (11/12)). Based on these results some 
probiotics can successfully be used as inhibitors of pathogen adhesion, but results are in 
particular affected by the pathogens tested [71].  
Production of antimicrobial substances is another mechanism by which probiotics may protect 
against infections. Production of acidic metabolites such as lactic and acetic acid and the pH 
reductive effect is one example [109]. Acid production by Bifidobacterium infantis has been 
observed to inhibit growth of E. coli O157 and S. Typhimurium [110] and several studies with 
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Lactobacillus spp. have demonstrated inhibition of growth of human pathogens due to acid 
production [109]. 
Anti-bacterial substances distinct from lactic and acetic acid are also produced by lactobacilli 
and bifidobacteria [109]. An example of such is the non-bacteriocin antibacterial component 
produced by L. acidophilus strain LA1 with demonstrated in vitro activity against a range of 
Gram-positive and Gram-negative pathogens including S. aureus, L. monocytogenes, 
Pseudomonas aeruginosa and S. Typhimurium [111]. For bifidobacteria antimicrobial activity 
of two strains isolated from infant stools was demonstrated with viability of selected strains of 
Klebsiella pneumoniae, Yersinia pseudotuberculosis, E. coli, S. aureus, P. aeruginosa and S. 
Typhimurium greatly reduced after 1 or 3 hours of incubation with culture supernatants from 
either of two bifidobacterial strains [112]. 
The last antagonistic mechanism of probiotics described here is the ability to stimulate the 
immune system. The use of probiotics has been implicated in the maturation of the immune 
system in infants, in regulation of the Th1/Th2 balance and in prevention of immune-
mediated diseases, such as allergies [113-115]. However, these topics are beyond the scope of 
this thesis and here focus will be on examples of immune modulation with positive effects on 
protection against Salmonella infections.  
In studies investigating prevention of Salmonella infections probiotics have been shown to 
influence a number of immune effects that improve host resistance to the pathogen e.g. the 
activity of phagocytic cells, cytokine production and levels of immunoglobulins (Ig) [113].  
Increased phagocytic activity of blood and peritoneal cell preparations was observed in 
studies with mice fed L. rhamnosus HN001 or B. lactis HN019 prior to S. Typhimurium 
infection [78,79]. These findings were accompanied by enhanced survival rates, reduced 
numbers of Salmonella in the liver and spleen and increased titers of Salmonella-specific 
antibodies in serum, mucosa and intestinal fluids.  
A heat-killed multi-strain mixture of L. acidophilus was seen in vivo to reduce serum TNF-α 
levels and to protect against S. Typhimurium infection in mice. In vitro, the probiotic mixture 
stimulated the phagocytic activity of murine macrophage cells. [84]. Furthermore, oral 
administration of B. longum to mice prior to S. Typhimurium infection increased the survival 
rate and reduced the production of IFN-γ by the spleen, suggesting a reduced inflammatory 
response as the protective effect of the probiotic administration [81].   
The effect of probiotics on the immune response towards an attenuated S. enterica serovar 
Typhi (S. Typhi) vaccine in humans was investigated by Link-Amster et al. [116]. Human 
volunteers consumed fermented milk containing L. acidophilus La1 and bifidobacteria B12 (a 
commercial mixed culture) for three weeks or were restricted from consuming fresh 
fermented products (control group). When an attenuated S. Typhi was given to the volunteers, 
to mimic an enteropathogenic infection, the titer of specific serum IgA to S. Typhi was 4-fold 
increased in the probiotic group compared to 2.5-fold in the control group, indicating that 
probiotics may enhance the effectiveness of oral a Salmonella vaccine in humans [116]. 
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3.2 NON-DIGESTIBLE DIETARY CARBOHYDRATES  
Non-digestible dietary carbohydrates are another approach to obtain health benefits of 
intestinal beneficial bacteria already present in the intestinal tract and a healthy and balanced 
gut microbiota has been described as one that is predominantly saccharolytic with significant 
numbers of bifidobacteria and lactobacilli [4].  
The concept of prebiotics was initially defined by Gibson & Roberfroid [30] as “non-
digestible food ingredients that beneficially affect the host by selectively stimulating the 
growth and/or activity of one or a limited number of bacteria in the colon [30]. Since then the 
definition has been refined by Gibson et al. [24] and prebiotics are now defined as “ 
selectively fermented ingredients that allow specific changes, both in the composition and/or 
activity of the gastrointestinal microbiota that confers benefits upon host well-being and 
health”.  
According to Gibson and Roberfroid [24] a food ingredient has to fulfil three criteria to be 
classified as prebiotic:  
 
A prebiotic should: 
1) Resist gastric acidity, hydrolysis by mammalian enzymes and gastrointestinal absorption. 
2) Be fermented by the intestinal microbiota. 
3) Selectively stimulate the growth and/or activity of intestinal bacteria associated with health 
and wellbeing. 
  
Referring to these three criteria only inulin and FOS, galacto-oligosaccharides (GOS) and 
lactulose have been classified as prebiotic substrates [24]. Among other prebiotic candidates 
evaluated in the study by Gibson and Roberfroid [24] are isomalto-oligosaccharides, 
lactosucrose, xylo-oligosaccharides (XOS), soyabean oligosaccharides and gluco-
oligosaccharides.  
One aspect of critical importance to the prebiotic concept is the selective stimulation of 
bifidobacteria and lactobacilli at the expense of other bacterial groups [117,118]. The 
selectivity may be affected by characteristics such as the type of glycosidic linkage, degree of 
branching and the degree of polymerization (DP), being the number of repeat monomer units 
in a polymer chain [119]. The DP influences where in the large intestine fermentation occurs. 
Non-digestible carbohydrates with a low DP reach the proximal colon, where substrate 
availability and bacterial growth is generally high and the pH is low (5-6) as a result of 
intense acid production. In contrast, carbohydrates with a higher DP e.g. inulin may be 
available for fermentation in the distal colon [3,120].   
The indigestibility of prebiotics and other ND dietary carbohydrates is a result of the ß-
configuration of the glycosidic bound between monosaccharides, whereas human 
gastrointestinal digestive enzymes are specific for α-glycosidic bounds [8,20]. However, ND 
dietary carbohydrates with α-configuration also exists e.g. polydextrose and pectins. In 
principle, these can be degraded by human digestive enzymes, but reach the colon largely 
undigested due to their high molecular weight [121,122].  
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3.2.1. HEALTH BENEFITS OF NON-DIGESTIBLE DIETARY CARBOHYDRATES  
ND dietary carbohydrates have the potential to modulate intestinal bacterial fermentation 
patterns, which may in turn affect several physiological functions [123]. A large number of 
health-promoting effects of prebiotics/ND dietary carbohydrates have been hypothesized 
(Table 2). These are generally the same as suggested for probiotics, since the primary effect of 
prebiotics is through the interaction with the intestinal microbiota [20,123,124]. Although far 
from all postulated effects of prebiotics have been fully demonstrated [20,124], a bifidogenic 
effect of prebiotics and other potential prebiotic carbohydrates have been demonstrated as 
described in section 3.2.2 for the substrates investigated in the present thesis.  
 
Table 2. Potential health-benefits of prebiotics/non-digestible dietary carbohydrates  
Effects References 
Prevention of diarrhoea (traveller’s and antibiotic-associated)  [125,126] 
Treatment of inflammatory bowel diseases [127,128] 
Prevention of allergic disorders [129,130] 
Immune modulation [131,132] 
Improved mineral absorption (mainly Ca and Mg) [133-135] 
Regulation of lipid metabolism [136,137]  
Improved bowel habit [117,138-140] 
Reduced risk of colon cancer development [141-144] 
 
One potential beneficial effect of consuming ND dietary carbohydrates is improved bowel 
habit with relief of constipation, reduced transit time, and increased faecal bulking [117,138-
140]. Reduced transit time, as a result of increased bacterial biomass and hence increased 
stool frequency, may thus decrease the exposure time of the gut epithelium to potential 
carcinogens of dietary origin [20]. Diet and bacterial metabolism are factors, in addition to 
genetic susceptibility, that plays an important role in the risk of developing colon cancer [118] 
and consumption of diets high in red meat have been associated with this type of cancer [145-
147]. In contrast, an inverse association between intake of dietary fibre and incidences of 
colon cancer have been demonstrated [148,149]. Release and accumulation of potential 
carcinogen by-products from protein degradation such as ammonia, phenols, indoles and 
amines [150] may thus be reduced by diets rich in fibre and hence, by changes in the 
microbial composition towards primarily saccharolytic bacteria (e.g. bifidobacteria and 
lactobacilli) [106,150].  
 
A number of in vivo studies have investigated the potential of prebiotics on prevention of 
Salmonella infections in rodents [83,85,151-157] (discussed in section 4.2). Besides the 
potential protective effect of prebiotics exerted through modulation of the gut microbiota, 
prebiotics and other ND dietary carbohydrates may also protect against pathogen adhesion 
and invasion by receptor mimicry [158,159]. Attachment to epithelial cell surface receptors is 
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often the first step in the pathogenesis of entero-pathogens and prebiotics acting as receptor 
analogues might inhibit infection, with pathogen binding to soluble oligosaccharides rather 
than to host cell receptors [107,158,160]. For example, GOS have been shown in vitro to 
reduce adherence of enteropathogenic E. coli (EPEC) to HEp-2 and Caco-2 cells, and the anti-
adhesive activity of GOS was more effective than of both FOS and inulin [160]. Similarily, 
GOS was found to reduce the invasion of S. Typhimurium SL1344 and LT2 to HT29 cells 
lines [155]. Furthermore, pectins and pectic oligosaccharids reduced the activity of E. coli 
O157:H7 produced shiga toxin, likely by inhibiting binding of the toxin [161].  
3.2.2. APPLICATION AND BIFIDOGENIC EFFECT OF INVESTIGATED CARBOHYDRATES 
Besides the potential for modulating the gut microbiota, ND dietary carbohydrates are used in 
the food industry as bulging agents and as fat and sugar replacers [119]. The chemical 
structure, natural sources and functional properties of the ND dietary carbohydrates 
investigated in the present thesis are described below, along with studies on their effects on 
the composition of the gut microbiota from human studies, if possible, or from animal or in 
vitro studies. An overview of all tested carbohydrates is given in Table 3.   
INULIN AND FRUCTO-OLIGOSACCHARIDES 
Inulin and fructo-oligosaccharide (FOS) are by far the best 
studied prebiotics. Both compounds are polymers of D-
fructose units linked by β-2.1-glycosidic bounds often with 
an α-1.2-linked D-glucose at the terminal end of the molecule 
(Figure 5) [1,118]. 
Inulin occurs naturally in a variety of vegetables and fruits as 
a source of carbohydrate storage with onion, banana, garlic 
and leek being the most common natural sources of inulin 
[1]. Commercial inulin is essentially produced from chicory 
roots. Chicory inulin is a mixture of oligomers and polymers 
with a DP ranging from 2-60 and an average DP of 12.  
FOS is prepared from inulin by enzymatic hydrolysis 
yielding oligomers with a DP of ~2-7 and an average DP of 4 
[1]. Alternatively, FOS can be synthesized using fungal β-
fructosidases by transfructosylation. In this process fructose 
units are added to sucrose molecules by β-2.1-linkages 
typically yielding oligomers with a DP of 2-4 [120].  
In the food industry inulin is used as gelating agent and as a 
fat replacer, whereas FOS is used as a sugar replacer with a sweetness of ~35% compared to 
sucrose and a low caloric value of 1.5 kcal g
-1
 (sucrose 4 kcal g
-1
) [1,162]. 
The inulin (Orafti ST-gel) used in the present thesis is a white, odourless, soluble powder 
extracted from chicory roots. The inulin content is ~92% with the remaining 8% being a 
mixture of glucose, fructose and sucrose. It has an average DP of ≥10 and a sweetness of 10% 
Figure 5. Chemical structure of 
inulin and fructo-oligosaccharide. n 
equals the number of fructose units 
[20].  
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compared to sucrose. The fructo-oligosaccharides (Orafti P95) used in the thesis has an oligo-
fructose content of 95%, a 30% sweetness compared to sucrose and a DP of 2-8 
(www.orafti.com). 
 
Both inulin and FOS are regarded as bifidogenic in infants and adults, although variations in 
the bifidogenic effect have been observed [64,120]. In healthy adults the lowest dosage of 
inulin and FOS with a demonstrated bifidogenic effect is 5 g/day based on analysis of faecal 
samples [64,163-165]. In infants a daily dosage of as low as 1.25 g inulin and 1.7 g of an 
inulin/FOS mixture has been reported as bifidogenic [64,166,167]. In addition, several studies 
report an increase in lactobacilli in infant stools [64]. Besides the reported effects on the 
faecal microbiota Langlands et al. [168] found, that a mixture of inulin and FOS (7.5 g/day of 
each substrate) supplemented to adults also increased numbers of bifidobacteria and 
lactobacilli in the mucosa-associated microbiota of the large intestine, with the largest effect 
observed in the distal colon.  
Although inulin and FOS are intended to selectively promote growth of bifidobacteria and 
lactobacilli, they may also affect growth of other gut bacteria. In some infant or adult studies a 
reduction in potentially harmful bacteria such as Bacteroides spp. and Clostridium spp. was 
observed [139,169,170], while these bacterial genera were stimulated in other studies 
[163,164,171,172] demonstrating that inulin and FOS can also enhance non-target bacteria.  
GALACTO-OLIGOSACCHARIDES 
Galacto-oligosaccharides (GOS) are chains of D-galactose monomers linked by β-1.4 or β-1.6 
bounds with a terminal α-1.4 bound D-glucose molecule (Figure 6). GOS is naturally present 
in both human milk, particularly in colostrum, and cow’s milk and often has a DP of ~2-5 
[162,173]. For commercial products GOS is usually produced by β-galactosidase treatment of 
whey-derived lactose, which is formed as a by-product from the dairy industry [162]. For 
GOS production β–galactosidases from various fungi, yeast and bacteria are used resulting in 
differences in the glycosidic linkages in the final product e.g. β-1.4 or β-1.6 [162,173].  
GOS preparations have a caloric value of only 1.7 kcal g
-1
 and a third of the sweetness of 
sucrose making the oligomer useful as a sweetener in the production of foods and beverages. 
Furthermore, GOS is used to increase the texture and mouth feel of a variety foods as well as 
a bulking agent [162]. The GOS used in the present thesis was provided by Danisco Health 
and Nutrition, Kantvik, Finland. The oligomer had a DP of ~2-6, but may contain traces of the 
starting material lactose and monomers of glucose and galactose.  
 
 
Figure 6. Chemical structure (β-1.6) of galacto-oligosaccharides. n equals the number of galactose units [20]. 
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The prebiotic properties of GOS have in particular been investigated in infants fed formulas 
supplemented with oligosaccharides. A mixture of 10% FOS and 90% GOS has been 
developed to simulate the carbohydrate composition of human milk with the intention of 
using the mixture in infant formulas [162]. Bifidobacteria dominate the gut microbiota of 
breast fed babies, which is believed to result from their utilization of milk oligosaccharides, 
including GOS [14,15,162]. Infants fed formulas supplemented with the FOS/GOS mixture 
(4-8 g/L) was seen to develop a faecal microbiota that resembles that of breast fed babies, 
with increased numbers of bifidobacteria and lactobacilli compared to infants fed standard 
formulas [174-176].  
In  studies with adults a bifidogenic effect of GOS has also been observed [177,178], with a 
daily dosage of 10 g GOS recommended to obtain such an effect [162,173]. In addition to the 
increase in faecal bifidobacteria GOS stimulated the growth of lactobacilli in one study [177]. 
In vitro, microbial changes induced by GOS fermentation were seen to alter the fermentative 
activity of a human faecal inoculum resulting in a reduction in pH and in an increase in SCFA 
concentrations as compared to fermentation without GOS [178]. 
XYLO-OLIGOSACCHARIDES  
Xylo-oligosaccharides (XOS) are oligomers of xylose units linked by ß-1.4 linkages (Figure 
7) [118]. XOS can be produced at industrial scale by chemical/enzymatic treatment of xylan-
rich materials. Typical raw materials for XOS production are hardwood, corn cobs, straws, 
bagasses, hulls and bran [179]. The resulting XOS products typically have a DP of ~2-4 
[117]. The sweetness of xylobiose (DP=2) is about 30% compared to sucrose making is useful 
as a low calorie-sweetener. In addition, the oligomer is commercially used as a food 
ingredient in Japan in FOSHU foods (Food for Specified Health Use) [179].  
The XOS used in the present thesis (provided by Danisco Health and Nutrition, Kantvik, 
Finland) was prepared from xylan and had a purity of >92% with xylose compounds ranging 
from DP2 to DP10 (majority of DP2 and DP3). 
 
 
Figure 7. Chemical structure of xylo-oligosaccharide, n equals the number of xylose units [20]. 
 
Xylo-oligosaccharides are considered as promising prebiotic candidates [24], that have been 
shown to be effectively fermented by several bifidobacterial species (B. bifidum, B. infantis, 
B. longum, B. adolescentis, B. angulatum, B. catenulatum and B. lactis) in in vitro mono-
cultures. In contrast, utilization of XOS by strains of Lactobacillus was less efficient 
[180,181]. In mixed faecal batch cultures and semi-continuous fermentation systems, 
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inoculated with a human faecal microbiota, stimulation of bifidobacteria by XOS has also 
been demonstrated [182-184].  
In vivo, studies with rats fed diets supplemented with 6% XOS have reported increased 
numbers of caecal and faecal bifidobacteria [142,185], while numbers of lactobacilli were 
unaffected [185]. In the study by Campbell et al. [185] the bifidogenic effect was 
accompanied by a reduced faecal and caecal pH and increased concentrations of caecal 
SCFAs. In both studies the bifidogenic effect of XOS was greater that observed for FOS 
[142,185].  
In humans consumption of XOS for three weeks by elderly aged ≥65 increased faecal 
numbers of bifidobacteria, decreased faecal pH and increased faecal moisture [186].    
Growth of other intestinal bacteria (Enterococcus spp., Bacteroides spp., Clostridium spp. and 
E. coli) was generally very limited or absent in the in vitro mono-culture studies. Only few 
strains of Enterococcus, Bacteroides and Clostridium grew on XOS [180,181].  
CEREAL BETA-GLUCAN  
Beta-glucan (ß-glucan) is a major component of the cell wall of commercially important 
cereals including oat, barley, rye and wheat [187]. The structure of cereal ß-glucans are linear 
chains of D-glucose units linked by ß-1.3 and ß-1.4 glycosidic bounds. The structure consists 
of two main building blocks of three (cellotriosyl) or four (cellotetraosyl) ß-1.4 bound D-
glucose units separated by a single ß-1.3 binding (Figure 8). The two blocks make up more 
than 90% of the ß-glucan structure. The remaining part of the polymer is mainly composed of 
longer cellulosic sequences of 5-14 D-glucose units [187,188]. The DP of ß-glucans is 
variable and may be >500 [132].  
 
 
Figure 8. Chemical structure of cereal beta-glucan presented as a cellotriosyl unit. Modified from [188]. 
 
The use of ß-glucans in the food industry is mainly due to their gelling capacity and ability to 
increase the viscosity of aqueous solutions. ß-glucans may also be used as a fat replacer in 
calorie-reduced foods. The polymer has successfully been used in the manufacture of several 
food products including cereals, pasta, noodles, bakery products, dairy products and meat 
products [187]. The ß-glucan used in the present thesis was the high purity (75%) barley ß-
glucan Glucagel™ purchased from GraceLinc Ltd.   
 
In vitro mono-culture studies with barley ß-glucan demonstrated that none of the selected 
strains of bifidobacteria and lactobacilli were able to ferment the polysaccharide. Among 
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other tested gut bacteria all Bacteroides isolates and Clostridium beijerinckii fermented ß-
glucan, whereas growth of E. coli and Enterococcus isolates was not supported [180].  
Degradation of ß-glucooligomers, prepared by enzymatic hydrolysis of ß-glucan, was shown 
to support the growth of L. rhamnosus GG, whereas utilization of the oligomers by strains of 
L. acidophilus, Bifidobacterium spp., Bacteroides spp., C. difficile and E. coli was generally 
poor [181]. Based on these results ß-glucan is unlikely to directly promote growth of 
bifidobacteria and lactobacilli in the gut, but it may support growth of Bacteriodes spp.  
PECTINS 
Pectins are complex polysaccharides present in plant cell walls 
and are mainly composed of a backbone of α-1.4-linked 
galacturonic acid units [189]. The pectin polysaccharides are 
divided into five structural classes designated homogalacturonan 
(HG), xylogalacturonan (XGA), apiogalacturonan (AGA) and 
rhamnogalacturonan I (RG-I) and II (RG-II) [122].  
HG is a polymer of α-1.4-linked D-galacturonic acid (GalpA) 
that can account for more than 60% of the pectins in the plant 
cell wall. The galacturonic acid units may be partly methylated at 
C-6 or acetylated at O-2 or O-3 (Figure 9). Based on HP 
extracted from apple, beet and citrus the DP of HP ranges from 
approximately 70-100 [122].    
The remaining pectin classes are HG substituted with side chains 
or with differences in the GalpA backbone. XGA is HG 
substituted with D-xylose at C-3 of the GalpA units. AGA is 
substituted with D-apiose at C-2 or C-3 and is found in aquatic 
plants. RG-I has a backbone of repeating units of galacturonic 
acid and rhamnose [→α-D-GalpA-1.2-α-L-Rhap-1.4→]n with 
side chains of α-arabinan, ß-galactan and type-I arabinogalactan. 
RG-II is an even more complex structure consisting of a HG 
backbone (7-9 residues long) with four side-chains (designated 
A-D) incorporating another ten different monosaccharides into 
the structure [122].  
For commercial production pectins are extracted from citrus peel and apple pomace. The most 
important function of pectins is in the production of jams and jellies due to its gel forming and 
water holding capacity [189,190]. Examples of other useful applications of pectin in the food 
industry are as thickener and stabiliser in dairy products, as texturizer in low calorie soft 
drinks that lacks the mouth feel provided by sucrose and in the control of the size of ice 
crystals in ice [189]. The pectin used in the present thesis was raw apple pectin purchased 
from Obipektin AG with galacturonic acid constituting ~75% of the polymer. 
 
Figure 9. Chemical structure  
of pectin belonging to the 
structural class homo-
galacturonan (HG) [122]. 
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The bifidogenic effect of pectins and pectic-oligosaccharides have been studied by Olano-
Martin et al. [191]. The pectins investigated were citrus pectin and apple pectin and their 
derived oligosaccharides. In mono-cultures growth rates of selected gut bacteria 
(Bifidobacterium spp., Lactobacillus spp., Bacteroides spp., Clostridium spp., Enterococcus 
faecalis and E. coli) were generally higher on apple pectin and apple pectin oligosaccharides 
compared to citrus pectin/oligosaccharides. The pectins and the oligosaccharides did not 
particularly promote growth of bifidobacteria or lactobacilli in mono-cultures. However, in 
mixed cultures, inoculated with a human faecal microbiota, a significant increase in 
bifidobacteria was observed for both pectins and oligosaccharides, but the bifidogenic effect 
was more pronounced for the oligosaccharides compared to their parent pectins. Still, when 
compared to fructo-oligosaccharides the pectic-oligosaccharides were not a particularly 
effective prebiotic candidate [191].  
Other studies investigating the ability of bifidobacteria to ferment pectin or pectic-
oligosaccharides in vitro found that the majority of 229 investigated strains (29 species) did 
not ferment pectin [192], whereas Mandalari et al. [190] demonstrated a bifidogenic effect of 
an extract from citrus peel rich in pectic-oligosaccharides. The observed bifidogenic effect 
was stronger than observed for fructo-oligosaccharides. However, the extract also contained 
small amounts of other carbohydrates (rhamnose, arabiose, xylose, mannose, galactose, and 
glucose) that might contribute to the growth of bifidobacteria.  
POLYDEXTROSE  
Polydextrose (PDX) is a water-souble polymer of glucose with a low caloric value (approx. 1 
kcal g
-1
). In the food industry PDX is used as a bulking agent, texturizer and thickener and as 
a sugar and fat replacer. It is synthesized by random polymerization of glucose molecules (α-
1.6 glycosidic bounds predominate) and has a complex structure with a DP ranging from 1-
100 with an average of ~10 [119,121,193]. 
The PDX used in the present thesis was provided by Danisco Health and Nutrition, Kantvik, 
Finland, with the majority (~90%) of the polymer having a DP of 3-30 and an average DP of 
12. 
 
Effects of polydextrose intake on physiological functions in human volunteers have been 
investigated by Zhong et al. [194]. Volunteers were assigned to groups consuming 4, 8 or 12 
g PDX a day for a period of four weeks or to a control group with no intake of PDX. All 
concentrations of polydextrose improved bowel function, increased faecal weights and 
decreased faecal pH proportionally with PDX intake. A daily intake of 8 and 12 g PDX 
increased faecal concentrations of acetate, butyrate and isobutyrate. For all groups consuming 
polydextrose a decrease in faecal Bacteroides spp. (B. fragilis, B. vulgatus and B. 
intermedius) was observed, whereas Lactobacillus spp. and Bifidobacterium spp. increased 
relatively to polydextrose intake. Based on these results a daily intake of 4-12 g/day 
polydextrose has beneficial effects on gut health with proliferation of favourable groups of 
gut bacteria and an acidification of the gut environment.  
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Table 3. Chemical structure, natural source and method of manufacture of non-digestible carbohydrates 
Carbohydrate Chemical structure DP
1
 Natural source/methods of manufacture 
Inulin and FOS
2
 D-fructose units linked by β-2.1 
bounds. Terminal α-1.2-linked 
D-glucose. 
Inulin 2-60 
FOS ~2-7 
Onion, banana, garlic, leek and chicory root 
Inulin: Extraction from chicory root. 
FOS: Hydrolysis of chicory inulin or 
enzymatic synthesis.  
GOS
3
 D-galactose units linked by  
β-1.4 or β-1.6 bounds. Terminal 
α-1.4 bound D-glucose unit. 
~2-5 Human and cow’s milk.  
Enzymatic synthesis from lactose. 
XOS
4
 Xylose units linked by ß-1.4 
bounds. 
~2-4 Bamboo shoots.  
Produced by chemical/enzymatic treatment 
of xylan-rich material. 
Cereal ß-glucan Linear chains of  
D-glucose units linked by ß-1.4 
or ß-1.3 bounds. 
Variable, 
>500 
Oat, barley, rye and wheat. 
Extraction from natural sources. 
Pectins Largely composed of a 
backbone of α-1.4-linked 
galacturonic acid. Five 
structural groups with variation 
in side chains and backbone. 
Variable, 
70-100 
Plant cell walls. 
Commercially produced from citrus peel 
and apple pomace. 
Polydextrose Composed of glucose units,  
α-1.6 bounds predominate 
Variable, 
1-100 
Chemical synthesis by random 
polymerization of glucose. 
1
Degree of polymerization, 
2
Fructo-oligosaccharide, 
3
Galacto-oligosaccharide, 
4
Xylo-oligosaccharide 
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4. THE FOOD-BORNE PATHOGEN SALMONELLA TYPHIMURIUM 
Salmonella is a genus of Gram negative bacteria that are a major cause of food-borne illness 
globally [195]. In 2007, a total of 151.995 confirmed cases of human salmonellosis were 
reported in the EU (31.1 cases per population of 100.000). The specific age distribution 
revealed that the majority of reported cases were within the group of 0-4 year old children 
(125.4 cases per population of 100.000). This was approximately three times higher than the 
rate of cases in the age group 5-14 years and six to nine times higher than the incidence of 
cases reported for those aged ≥15 [196]. 
The two most common reported Salmonella serovars in 2007 in the EU were S. Enteritidis 
and S. Typhimurium. Together the two serovars represented 81% of known types in human 
cases, with S. Enteritidis accounting for 64.5% and S. Typhimurium for 16.5%. Salmonella 
was most often isolated from fresh meat and meat products, particularly of poultry origin, 
followed by pig meat. Other food products less frequently associated with Salmonella were 
eggs, fishery products, vegetables and fruit [196].  
4.1 INTESTINAL PATHOGENESIS OF S. TYPHIMURIUM  
S. Typhimurium infection in susceptible mice provides a well-characterized model for S. 
Typhi pathogenesis in humans. After infection with S. Typhimurium mice develop a systemic 
disease similar to human typhoide fever [197].  
After oral exposure, a proportion of ingested S. Typhimurium cells survive the acidic 
environment in the stomach and arrive in the small intestine, where the pathogen translocates 
through the epithelial cell layer [198]. The primary site of S. Typhimurium invasion is 
believed to be M cells located in the follicle associated epithelium (FAE) of Peyer’s patches 
in the distal small intestine [197,199]. Following M cell invasion Salmonella infect 
phagocytes, preferentially macrophages, in the lamina propia whereby the pathogen gains 
access to the lymphatic system and bloodstream and subsequently the liver and spleen [200].  
M cell invasion by Salmonella is believed to be mediated, at least partly, by a specific adhesin 
- the long polar fimbria (LPF) [199]. This has been observed with lpf mutants recovered in 
lower numbers from Peyer’s patches, mesenteric lymph nodes, liver and spleen of mice 
compared to recovery of wild-type Salmonella [201]. Other fimbria, besides LPF, suggested 
to also contribute to M cell targeting is the type 1 fimbria, capable of binding to mannose 
oligosaccharide receptors on host cells [202].    
M cells are specialised in delivering antigens from the gut lumen to phagocytic cells via 
transepithelial vesicular transport [198,203] and are characterised by a reduced number of 
microvilli and a thin glycocalyx compared to enterocytes. These characteristics, combined 
with reduced quantities of secretory IgA at the FAE surface, makes M cells vulnerable to 
infection by pathogens [199]. In addition to M cell invasion S. Typhimurium infection has 
been associated with subsequent M cell and FAE destruction providing easy and less 
restricted translocation across the epithelial surface [204].  
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Invasion of M cells by Salmonella involves effector proteins encoded by the “Salmonella 
pathogenicity islands” (SPI), including SPI-1 and SPI-2. Both SPI-1 and SPI-2 encodes “type-
III-secretion-systems” (T3SS), of which T3SS encoded by SPI-1 is important for invasion of 
M cells and SPI-2 T3SS for intracellular survival in host macrophages [197,205]. Following 
contact of Salmonella with M cells the SPI-1 T3SS forms a needle-like structure, through 
which bacterial proteins are injected into the cytosol of host cells [205]. Some of these 
proteins have actin-binding actitivites, resulting in cytoskeletal rearrangements leading to 
bacterial internalization [197,205]. The importance of SPI-1 in the virulence of Salmonella 
has been demonstrated with Salmonella SPI-1 mutants showing reduced abilities to invade M 
cells [206-208].  
The ability of Salmonella to survie in macrophages is required for development of a systemic 
infection [200]. Intracellulary within macrophages Salmonella reside in unique membrane 
bound vacuoles, termed the Salmonella containing vacuole (SCV), which permit intracellular 
survival and replication [195,209]. Within the vacuole Salmonella escapes contact with some 
of the antimicrobial components produced by macrophages. Examples are reactive oxygen 
species (ROS) and reactive nitrogen intermediates (RNI) produced in response to Salmonella 
infection. Salmonella is capable of inhibiting expression or delivery of the enzymes involved 
in the production of ROS and RNI to the SCV in an SPI-2 dependent manner [210]. Other 
examples of SPI-2 functions are the role of SPI-2 effector proteins in the control of the 
intracellular position of the SCV [209] and in inhibition of maturation of the SCV into a 
phagolysosome [211]. 
The liver and spleen are the two main sites of Salmonella proliferation within macrophages. 
The precise mechanisms involved in spread of Salmonella to new cells are not fully clear, but 
may invole Salmonella residing within the macrophage for the lifetime of the hoste cell 
followed by infection of new macrophages [200]. Furthermore, Salmonella is capable of 
inducing macrophage cell-death by at least two mechanisms. Either a rapid macrophage cell 
death is induced in a SPI-1 dependent manner or a delayed macrophage cell death is induced 
in a SPI-2 dependent manner [200,212]. Dead or dying macrophages infected by Salmonella 
may then be phagocytosed by new macrophages providing a new site of survival and 
replication of the pathogen [200].  
The bacterial distribution and the lesions in the liver and spleen of mice infected with S. 
Typhimurium resemble those observed in humans suffering of typhoid fever [213]. In murine 
infections extensive growth of Salmonella in the organs leads to death with a lethal load of 
10
8
 viable bacteria per. organ [214]. Death is believed to result from organ failure with 
pathological signs of infection being enlarged Peyer’s patches, liver and spleen and with 
organs appearing pale and friable [213,214].   
 
Alternatives to the classical M cell dependent route of Salmonella invasion have also been 
described suggesting enterocytes as potential targets for invasion [215]. Moreover, Vazquez-
Torres et al. [216] found that a non-invasive SPI-1-deficient S. Typhimurium strain can 
disseminate from the gut lumen of mice via CD18-expressing phagocytic cells. The CD-18 
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mediated route was proposed based on the observation that levels of the SPI-1-deficient 
Salmonella strain in the liver and spleen of CD-18 deficient mice were reduced compared to 
wild-type mice. In addition, dendritic cells can penetrate epithelial cells and take up 
Salmonella from the gut lumen [217]. Furthermore, S. Enteritidis infection in rats have 
demonstrated that the infection affects gene expression in the rat colon, suggesting that in 
addition to the ileum, the colon is also a target for Salmonella invasion [218].  
4.2 EFFECTS OF NON-DIGESTIBLE CARBOHYDRATES ON SALMONELLA INFECTIONS 
Several studies with probiotics have demonstrated protective effects against murine 
Salmonella infections [78-85]. Similarly, studies with prebiotics have investigated the effect 
on Salmonella infections in broilers [219,220], swine [221-223], rats and mice [83,85,151-
157]. In the following section focus will be on the effects of prebiotics and other ND dietary 
carbohydrates on Salmonella infections in rodents. 
Studies with mice and rats on prevention of Salmonella infections have demonstrated 
conflicting results. Some studies have demonstrated a protective effect of either prebiotics in 
combination with probiotics (synbiotics) [83,85] or of prebiotics alone [83,85,155-157], while 
others have demonstrated adverse effects of prebiotic consumption on Salmonella infections 
[151-154].  
Preventive effects of either prebiotics alone (inulin), probiotics (Lactobacillus acidophilus) or 
synbiotics (inulin and L. acidophilus) against Salmonella-induced liver damage in orally 
challenged mice (single dose of 5x10
6
 cfu) was investigated by Rishi et al. [85]. Both 
prebiotic (2 mg/day), probiotic (10
10
 cfu/day) and synbiotic administration resulted in 
decreased pathogen translocation to the liver seven days post-infection (p.i.). Furthermore, 
histology of liver sections showed that signs of liver damage were reduced by all three 
treatments as compared with non-supplemented challenged mice. However, generally a 
greater protection was observed for probiotics than for prebiotics and results did not indicate a 
synergistic effect of synbiotic administration.  
Improved protection of synbiotics was demonstrated in the study by Asahara et al. [83], 
where administration of B. breve (10
8
 cfu/day) combined with transgalactosylated 
oligosaccharides (TOS) (10 mg/day) improved the preventive effect of B. breve during a 7-
day period post oral S. Typhimurium challenge of mice (single dose of 10
2
 cfu), while TOS 
alone had no preventive effect on the infection.  
Studies on the preventive effect of prebiotics alone have demonstrated an increased survival 
rate of mice fed inulin during a 2-week period post S. Typhimurium challenge (single dose of 
10
3
 cfu). Still, a mortality rate of 60% was observed in the group fed a diet containing 10% 
inulin compared to >80% in the control group, whereas FOS supplementation did not increase 
the survival rate significantly [157]. Since infection by intraperitoneal injection of the 
pathogen was used in the study, the model does not mimic a food-borne infection and the 
reduced mortality rate may be a result of immune modulation rather that protection exerted by 
the mucosal barrier, although this was not investigated in the study.  
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The ability of prebiotics to stimulate the immune response towards Salmonella infections was 
investigated by Benyacoub et al. [156]. In an initial study, feeding mice a diet containing 5% 
of a FOS:inulin mixture (70:30%) for one week prior to oral immunization with an attenuated 
S. Typhimurium vaccine enhanced the specific antibody response towards Salmonella, 
stimulated the phagocytic activity of peritoneal macrophages, and enhanced cytokine 
production (IFN-γ and IL-12) by spleen cells. Whether the observed immunological effects 
were sufficient in providing protection against oral challenge with wild-type S. Typhimurium 
SL1344 (single dose of 3x10
7
 cfu) was investigated in a second study. Alone (without 
vaccination) the prebiotic mixture did not provide any protection against the infection. 
However, the survival rate of mice fed prebiotics prior to vaccination was increased to 73% 
compared to 40% in vaccinated control-fed mice, suggesting that fructo-oligosaccharides can 
enhance the efficiency of Salmonella vaccines.  
Besides inulin and FOS, GOS have been demonstrated to provide protection against murine S. 
Typhimurium infection [155]. In this study GOS was administrated to mice (2.5 g/kg) 30 
minutes prior to oral challenge with 10
7
 cfu S. Typhimurium SL1344. All mice dosed with 
GOS did not show clinical signs of infection throughout the study period (5 days). 
Furthermore, GOS reduced pathogen invasion of the liver and spleen (Day 3 and 4 p.i.) and 
reduced numbers of Salmonella in the ileum (Day 3 and 4 p.i.), colon (Day 3 p.i.) and cecum 
(Day 3 and 5 p.i.). However, the model chosen with GOS administration just prior to 
pathogen challenge does not mimic continuous ingestion of the prebiotic and it is likely, that 
the observed protective effect is an effect of blocking of pathogen adhesion rather than an 
effect of microbial changes induced by GOS [155]. 
Based on the studies above, there are indications of protective effects of prebiotics against 
Salmonella infections, although the studies by Benyacoub et al. [156] and Asahara et al. [83] 
demonstrate, that prebiotics alone are not sufficient in providing protection. In contrast, 
studies by a single group of researchers [151-154] have demonstrated increased, rather than 
decreased, translocation of Salmonella to extra-intestinal sites in prebiotic-fed rats. Diets 
containing 3-6% FOS or inulin were seen to increase translocation of S. Enteritidis (single 
dose of 10
8
-10
10 
cfu) measured as increased urinary excretion of nitrates and nitrites (NOx). 
Furthermore, prebiotic feeding increased the cytotoxicity of faecal water and faecal mucin 
excretion indicating mucosal irritation [151-154]. An important aspect of these studies was, 
that they were all based on low-calcium diets (0.80-1.20 g Ca/kg) and that a diet higher in 
calcium (4.0 g Ca/kg) could counteract most of the observed adverse effects [153]. The exact 
mechanism behind the FOS and inulin-induced adverse effects on intestinal permeability in 
these studies is unclear. However, it is suggested that the adverse effects is caused by 
increased production of lactic acid and other short chain fatty acids leading to irritation of the 
mucosal barrier [153,154] and that dietary calcium can counteract this effect by reducing the 
acidity of the gut environment [224].  
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5. AIM OF THE STUDY 
Based on studies with probiotics [78-84], demonstrating preventive effects on murine S. 
Typhimurium infections, the aim of the present thesis was to investigate whether similar 
protective effects could be demonstrated with prebiotics and other potential prebiotic dietary 
carbohydrates.  
Prebiotics are expected to improve gut health in a manner similar to probiotics. Still, they 
overcome some of the possible limitation of incorporating live bacteria in the diet. With 
prebiotics, problems associated with microbial survival during passage through the digestive 
tract is not a concern [118] and in contrast to probiotics, where introduced bacteria have to 
compete with the established microbiota, prebiotics target bacteria already colonising the gut. 
For these reasons, prebiotics may be a more efficient way of manipulate the gut microbiota 
[162].  
The initial focus of the project was prevention of S. Typhimurium infection with the idea of 
identifying new prebiotic substrates with preventive effects against S. Typhimurium SL1344 
infection. The studies were carried out using the BALB/c mouse model providing a model of 
human typhoid fever (Manuscript I). Subsequently, the intention of the thesis was to 
investigate effects of the carbohydrates with the best potential for pathogen inhibition on the 
composition of the gut microbiota, production of short chain fatty acids (SCFA) and immune 
modulation in host animals. However, results obtained from the animal studies demonstrated 
adverse rather that protective effects of prebiotic administration. Based on these results 
samples from animals showing reduced resistance to the Salmonella infection were chosen for 
further analysis with the aim of investigating changes in the intestinal microbiota and SCFA 
production which could potentially explain the observed differences in the infection 
susceptibility (Manuscript II).    
Since the carbohydrates investigated were shown not to be efficient in providing protection 
against the Salmonella infection, the research stay at CSIRO Food and Nutritional Sciences 
was an opportunity to investigate another potential health benefit of prebiotic consumption. 
Research at the division has previously demonstrated that resistant starch fed to rats attenuates 
protein-induced colonic DNA damage - an initial sign of colon cancer [54,225-228]. Thus, the 
aim of the study performed at CSIRO was to investigate whether a similar preventive effect 
could be demonstrated by XOS and inulin in vitro using a two-stage continuous fermenter. At 
present samples from fermentation of inulin is still being analysed, wherefore only results 
from fermentation of XOS are included in the thesis (Manuscript III). 
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Abstract 
Certain indigestible carbohydrates, known as prebiotics, are claimed to be beneficial for gut health 
through a selective stimulation of beneficial gut microbes including Bifidobacterium. However, 
stimulation of beneficial microbes does not necessarily imply a preventive effect against pathogen 
infection. We recently demonstrated a reduced resistance to Salmonella infection in mice fed diets 
containing fructo-oligosaccharides (FOS) or xylo-oligosaccharides (XOS). In the present study, faecal 
and caecal samples from the same mice were analysed in order to study microbial changes potentially 
explaining the observed effects on the pathogenesis of Salmonella. 
Denaturing gradient gel electrophoresis revealed that the microbiota in faecal samples from mice fed 
FOS or XOS was different from faecal samples collected before the feeding trial as well as from faecal 
profiles generated from control animals. This difference was not seen for caecal profiles. Further 
analysis of faecal samples by real-time PCR demonstrated a significant increase in the Bacteroidetes 
phylum, the Bacteroides fragilis group and in Bifidobacterium spp. in mice fed FOS or XOS. The 
observed bifidogenic effect was more pronounced for XOS than for FOS. The Firmicutes phylum and 
the Clostridium coccoides group were reduced by both FOS and XOS. Surprisingly, no significant 
differences were detected between faecal samples collected before and after pathogen challenge in any 
of the groups. Furthermore, no effect of diets on caecal concentrations of short chain fatty acids was 
recorded.  
In conclusion, diets supplemented with FOS or XOS induced a number of microbial changes in the 
faecal microbiota of mice. The observed effects of XOS were qualitatively similar to those of FOS, but 
the most prominent bifidogenic effect was seen for XOS. An increased level of bifidobacteria is thus 
not in itself preventive against Salmonella infections, since the same XOS or FOS-fed mice were 
previously reported to be more severely affected by Salmonella challenge than control animals. 
 
Keywords: Prebiotics, fructo-oligosaccharides, xylo-oligosaccharides, beneficial microbes, 
bifidobacteria. 
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Introduction 
Prebiotic carbohydrates were originally defined by Gibson and Roberfroid (1995) as “non-
digestible food ingredients that beneficially affect the host by selectively stimulating the 
growth and/or activity of one or a limited number of bacteria in the colon” and in many 
contexts, dietary carbohydrates are considered prebiotic if they increase the concentration of 
bifidobacteria in the intestine.   
Here, we report microbial changes induced by fructo-oligosaccharides (FOS) and xylo-
oligosaccharides (XOS) in the large intestine of mice challenged with Salmonella. Many 
studies of prebiotic effects have focused on consumption of FOS, which is an established 
prebiotic substrate with a demonstrated bifidogenic effect (Roberfroid et al., 1998). XOS, on 
the other hand, is regarded as an emerging prebiotic candidate (Roberfroid, 2007; Tuohy et 
al., 2005) of which a bifidogenic effect has been demonstrated in vitro (Crittenden et al., 
2002; Jaskari et al., 1998; Mäkeläinen et al., 2010) and in vivo (Campbell et al., 1997; Chung 
et al., 2007; Hsu et al., 2004).  
Both FOS and XOS are oligomers linked by ß-glycosidic bounds that are not hydrolysed by 
digestive enzymes produced in the small intestine (Swennen et al., 2006). Hence, they pass 
this part of the gut undigested and may function as a substrate for the large intestinal 
microbiota (Swennen et al., 2006; Tuohy et al., 2005). FOS are composed of monomers of 
fructose units linked by ß-2.1 bounds (Roberfroid, 2005; Tuohy et al., 2005), whereas the 
monomers in XOS are xylose units linked by ß-1.4 bounds (Tuohy et al., 2005).  
Even though several health benefits have been associated with the microbial effects of 
prebiotic consumption including protection against gastrointestinal pathogens (Asahara et al., 
2001; Buddington et al., 2002), studies from our lab (Petersen et al., 2009) as well as from 
Ten Bruggencate and co-workers (Bovee-Oudenhoven et al., 2003; Ten Bruggencate et al., 
2003; Ten Bruggencate et al., 2004; Ten Bruggencate et al., 2005) have demonstrated adverse 
effects on the susceptibility to Salmonella infections in mice and rats. More specifically, we 
found a markedly reduced resistance to infection by Salmonella enterica serovar 
Typhimurium SL1344 in mice fed diets supplemented with 10% FOS or 10% XOS (Petersen 
et al., 2009). Based on these results, the aim of the present study was to investigate changes in 
the faecal and caecal microbiota of the same mice, which could potentially explain the 
reduced resistance to pathogen challenge. Additionally, caecal short chain fatty acids (SCFA) 
were measured to determine whether their concentration was affected by changes in the 
microbiota. This is, to our knowledge, the first study describing diet-induced changes in the 
intestinal microbiota of mice exhibiting impaired resistance to Salmonella infections. 
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Materials and methods 
Experimental design and sample collection 
Faecal and caecal samples were obtained during a previously described feeding study with 
mice fed a selection of seven dietary carbohydrates (Petersen et al., 2009). The experimental 
diets based on the AIN-93 rodent diet (Reeves et al., 1993) were supplemented with 10% 
(w/w) dietary carbohydrates at the expense of cornstarch (Poulsen et al., 2002). The samples 
analysed were from mice fed diets supplemented with 10% fructo-oligosaccharides (FOS) or 
10% xylo-oligosaccharides (XOS) or from mice fed the cornstarch based control diet. FOS, 
DP 2-8 (Orafti P95, Beneo-Orafti, Tienen, Belgium) were purchased from Alsiano, Birkeroed, 
Denmark and XOS, DP 2-6 were kindly provided by Danisco Health & Nutrition, Kantvik, 
Finland. Briefly, 4 week-old conventional male BALB/c mice were purchased from Taconic 
Europe (Lille Skensved, Denmark) and housed individually for an acclimatisation period of 1-
2 weeks prior to onset of the feeding experiments. The mice were randomized (by weight) to 
groups of 8 animals (10 in the FOS group) and fed the experimental diets for three weeks 
prior to oral challenge with 10
7
 CFU Salmonella enterica serovar Typhimurium SL1344 (S. 
Typhimurium SL1344). For analysis of changes in the microbial composition fresh faecal 
samples were collected on the day prior to onset of the feeding study (start), after 3 weeks of 
feeding mice the experimental diets (before challenge, BC) and on Day 4 after Salmonella 
challenge (after challenge, AC). The contents of caeca were collected at euthanization on Day 
5 (Control N=7, FOS N=10, XOS N=7). Animal experiments were carried out under the 
supervision of the Danish National Agency for Protection of Experimental Animals. 
 
DNA extraction from faecal and caecal samples 
Either approximately 100 mg fresh faecal samples or half of the caecal content (approx. 10-
170 mg) was dissolved in 1 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8) and 
centrifuged at 2100 rpm for 2 min. The supernatants were centrifuged for 5 min. at 13.000 
rpm and pellets were dissolved in 1.2 ml TE-buffer. Samples were transferred to tubes 
containing 0.5 ml zirconia-silica beads (0.1 mm, Biospec Products) and 30 μl 10% sodium 
dodecyl sulphate (SDS). Bacterial cells were lysed by shaking for 4 min. on a bead-beater 
(Retsch MM300, VWR International) and centrifuged at 4500 rpm for 1 min. Supernatants 
were kept at -20 ºC until further treatment. DNA was extracted using the QIAamp DNA stool 
Mini Kit (Qiagen) according to the manufacturer’s instructions and stored in 200 μl elution 
buffer at -20 ºC until use.  DNA extraction failed for one faecal sample and two caecal 
samples.  
 
PCR amplification for DGGE 
PCR amplifications were performed in a total volume of 50 μl containing 10 μl DNA (diluted 
to ≤5 ng/μl from extraction), 20 μl 2.5x master mix (5Prime) and 40 pmol of each of the 
universal primers HDA1-GC and HDA2 targeting the V2-V3 region of the 16S rRNA gene 
(Walter et al., 2000). Amplification was performed on a Peltier Thermal Cycler model 
Tetrad2 (MJ Research) as a touchdown PCR. Initial denaturation was at 96 ºC for 5 min., 
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amplification was carried out in 20 cycles of denaturation at 94 ºC for 1 min., annealing at 65 
ºC 1 min. decreased by 0.5 ºC for each cycle, and elongation at 72 ºC for 1 min. This was 
followed by additionally 5 cycles of denaturation at 94 ºC 1 min., annealing at 55 ºC for 1 
min. and elongation at 72 ºC for 1 min. followed by a final elongation at 72 ºC for 5 min. The 
products (200 bp) were verified by gel electrophoresis before proceeding to the DGGE 
analysis 
 
Analysis of faecal and caecal microbiota by DGGE 
DGGE was carried out using a Dcode™ Universal Mutation Detection System instrument and 
a gradient former model 475 according to the manufacturer’s instructions (Bio-Rad). The gels 
were prepared from two 9% acrylamide (acrylamide-bis 37.5:1, Bio-Rad) stock solutions (0% 
and 100% in respect to urea and formamide concentrations) in 1xTAE (20 mM Tris, 10 mM 
acetate, 0.5 M EDTA, pH 7.4). The 100% stock solution corresponded to 7 M urea and 40% 
formamide. The gels were made with a denaturing gradient of 25-65%. 13 μl PCR product 
was mixed with 3 μl loading dye before loading. Gels were run in 1xTAE at 60 ºC for 16 
hours at 36 V, 28 mA, stained with ethidium bromide (Bio-Rad) for 15 min., and washed for 
20 min. Pictures of gels were taken by UV illumination using a Gel Doc apparatus (Bio-Rad). 
The BioNumerics software, version 3.0 (Applied Maths), was used for detection of bands and 
normalization of band patterns from the DGGE gels based on a marker loaded in every 5. 
lane. Cluster analyses were performed based on common and different bands using the binary 
coefficient Dice.  
 
Cloning and sequencing of selected bands from DGGE gels 
Bands of interest from the faecal DGGE profile of animals fed FOS or XOS were excised 
from the gels, placed in 40 μl sterile nuclease-free water (Ambion) and kept at 4 ºC for at least 
24 hours for diffusion of the DNA into the water. 8 μl of the DNA-containing water was used 
in a PCR with the HDA1/HDA2 primers without GC-clamp (94 ºC for 4 min., 20 cycles of 94 
ºC for 30 sec., 56 ºC for 30 sec. and 68 ºC for 1 min. followed by a final elongation at 68 ºC 
for 7 min.). Fresh PCR products were cloned using the TOPO TA Cloning kit for Sequencing 
(Invitrogen) according the manufacturer’s instructions. Briefly, PCR products were cloned 
into pCR 4-TOPO vectors and electroporated (2500 V, 400 Ω, 25 μF) into One Shot TOP10 
electrocompetent E. coli cells by use of a MicroPulser Electroporation apparatus (Bio-Rad). 
Colonies of E. coli cells cultured on selective Luria-Bertani plates (LB + 100 μg/ml 
ampicillin) were inoculated in LB broth (LB + 100 μg/ml ampicillin) overnight and plasmid 
DNA was isolated using the Qiagen Mini Spin Prep kit. PCR amplification with the HDA1-
GC and HDA2 primers was performed on the isolated plasmid DNA as described above. The 
PCR products were run on a DGGE gel along with the original DNA profile to confirm the 
melting behaviour of the excised band. From the isolated plasmid DNA the inserts were 
sequenced by GATC Biotech (Konstanz, Germany) using the primer T3. The obtained 
sequences were compared to existing sequences in the Ribosomal Database (RDP, Michigan 
State University, Release 10) and in the NCBI GenBank database using nucleotide blast.  
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Real-time PCR analysis  
Real-time PCR was performed on DNA extracted from faecal and caecal samples using the 
primers and amplifications conditions listed in Table 1. Amplifications were performed at 50 
ºC 2 min., 95 ºC 10 min. and 40 cycles of 95 ºC 15 sec. and 56-60 ºC 1 min. (Table 1) on an 
Applied Biosystems 7900HT instrument in a total volume of 20 μl containing 2 μl template 
DNA, 10 μl SYBR Green Supermix with premixed ROX (Bio-Rad), 200 nM primers and 
nuclease free water (USB Corporation) to a final volume of 20 μl. All results were calculated 
from a standard curve based on DNA from one animal with the threshold cycle (Ct) 
calculated by the ABI software as the PCR cycle, where amplification signals exceed the 
selected threshold value, also set by the software. Analysis of the standard curve allowed 
verification of PCR efficiencies close to 100% for the chosen PCR conditions. The calculated 
results were analyzed as ratios of species specific 16S rRNA levels relative to total bacterial 
16S rRNA levels in order to correct data for differences in total DNA concentration between 
individual samples. All samples were analyzed in duplicates. The specificity of the primers 
was verified by post-PCR melting curve analysis (56-95 ºC) and 2% agarose gels. In the 
analysis of the caecal samples animal no. 21 (FOS) and no. 27 (XOS) were excluded due to 
low DNA concentrations.  
 
Table 1. Primers and amplification conditions used for real-time PCR analysis 
Target group Primer Annealing/elongation temperature Reference 
Total bacteria 
1114F 
1275R 
60 ºC Denman and McSweeney, 2006 
Bacteroidetes phylum 
Bact934F 
Bact1060R 
60 ºC Guo et al., 2008 
Firmicutes phylum 
Firm934F 
Firm1060R 
60 ºC Guo et al., 2008 
B. fragilis group 
Bfr-F 
Bfr-R 
56 ºC Liu et al., 2003 
C. coccoides group 
g-Ccoc-F 
g-Ccoc-R 
58 ºC Matsuki et al., 2004 
Lactobacillus spp. 
Lacto-F 
Lacto-R 
58 ºC Rinttila et al., 2004 
Bifidobacterium spp. 
F-bifido 
R-bifido 
60 ºC Delroisse et al., 2008 
 
Analysis of SCFA composition in caecal contents 
Acetate, propionate, and butyrate in the caecal contents were analyzed using capillary 
electrophoresis and indirect UV detection by a method modified from Westergaard et al. 
(Westergaard et al., 1998). Half of the caecal content (approx. 10-170 mg) was diluted 30x 
(w/vol): initially 3x diluted in sterile water to gain a volume large enough for pH 
measurement followed by 10x dilution in an alkaline buffer (0.1 M Tris with 100 μM malonic 
acid as internal standard, pH 8.7). Samples were centrifuged (14000 g, 10 min., 4 ºC) and 
supernatants were sterile filtered by centrifugation (12000 g, 5 min., 4 ºC) using 0.45 μm 
Ultrafree-MC Centrifuge filter devices (Millipore). Samples were kept at -80 ºC until further 
analysis. A running buffer (2 mM 1.2.4-benzenetricarboxylic acid, 8 mM Tris, 0.3 mM 
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tetradecyl-trimethyl-ammonium bromide, pH 7.6) was prepared and sterile filtered (0.45 μm). 
Prior to analysis samples were diluted 2x in ½ running buffer (running buffer diluted 1:1 in 
sterile water). A standard containing 0-800 μM acetic, propionic and butyric acid diluted in ½ 
running buffer with 50.8 μM malonic acid was included in each run. Samples and standards 
were measured in duplicates. The analysis was performed using a fused-silica capillary with 
an id. of 75 μm and a length of 72/80.5 cm (72 cm to the detector and 80.5 cm total length) 
(Aligent Technologies). Prior to each run the capillary was pre-treated with 1 M NaOH for 30 
sec., 0.1 M NaOH for 1 min., water for 30 sec. and running buffer for 5 min. Samples were 
injected by pressure (35 mbar) and run at -30 kV for 15 min. at 20 ºC on a G1600A 
3D
Capillary electrophoresis instrument (Hewlett-Packard). Measurement of SCFA failed in 
animal no. 15 (FOS) and animal no. 27 (XOS) likely due to the degree of dilution (30x) of the 
caecal content at euthanization. 
 
Statistics 
Statistical analysis was performed using a one-way ANOVA on data with diet as the only 
variable (SCFA analysis and real-time PCR analysis of caecal samples). A two-way ANOVA 
was performed on data with time and diet as variables (number of DGGE bands and real-time 
PCR analysis of faecal samples). When ANOVA indicated a significant difference, Student’s 
t-test was used to compare means of treatments. All statistical analyses were carried out using 
SAS JMP 7.0. P-values of <0.05 were considered statistically significant. 
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Results 
Denaturing Gradient Gel Electrophoresis (DGGE) profiling 
Microbial diversity of the faecal and caecal samples was assessed by DGGE of 16S ribosomal 
genes amplified by universal bacterial primers. The number of bands did not differ 
significantly between dietary groups or between time points. The average number of bands 
(mean±SEM) in the faecal and caecal DGGE profiles from the control group were 15.6±0.9 
(start), 18.1±1.0 (before challenge, BC), 18.1±0.5 (after challenge, AC) and 17.0±2.0 
(caecum). In the FOS-fed group, the numbers were 16.7±1.3 (start), 15.6±1.4 (BC), 16.1±1.3 
(AC) and 15.0±1.9 (caecum), while the number of bands measured in profiles from the XOS-
fed group was 14.1±1.5 (start), 15.7±0.9 (BC), 16.8±1.2 (AC) and 17.3±1.1 (caecum).  
 
Dice cluster analysis of DGGE profiles revealed that feeding mice with FOS (Figure 1A) or 
XOS (Figure 1B) for three weeks induced changes in the composition of the faecal and caecal 
microbiota as compared to the start faecal profiles obtained before onset of the prebiotic 
feeding. Only in one animal in the XOS group (animal no. 29) the start profile did not cluster 
with the remaining start samples (Figure 1B). For most animals BC and AC profiles clustered 
next to each other, indicating that Salmonella challenge did not affect the profiles (Figure 1A 
and 1B). In mice fed the control diet,  DGGE profiles from start, BC and AC samples 
clustered together, while the caecal profiles clustered separately from the faecal profiles 
(Figure 1C), indicating that the faecal microbiota was different from the caecal microbiota in 
these animals. 
 
The faecal DGGE profiles from mice fed FOS or XOS at sampling time BC (Figure 2A) or 
AC (Figure 2B) were different from the control group, whereas the FOS and XOS profiles 
clustered together, indicating that the two oligosaccharides had comparable effects on the 
composition of the faecal microbiota. In contrast, DGGE performed on DNA extracted from 
the caecal contents did not cluster into feeding groups (Figure 2C). Profiles from faecal 
samples collected prior to feeding the prebiotic or control diets were similar between groups 
(data not shown). Three prominent bands present in most faecal BC and AC samples from 
FOS or XOS fed mice, but absent or weak in all samples collected before prebiotic feeding 
and in the control group were identified (marked 1, 2 and 3 in Figure 2A and 2B). Sequencing 
of two bands from BC profiles belonging to band class no. 1 or no. 2 revealed a similarity of 
≥95% to species within the genus Bacteroides. Band class no. 3 was found to represent 
members of the family Lachnospiraceae belonging to the order Clostridiales within the 
Firmicutes phylum. However, determining the identity of band no. 3 to genus level was not 
possible, probably due to the limited length (200bp) of the cloned PCR-product.  
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Figure 1. Faecal and caecal DGGE 
profiles of mice fed FOS, XOS or 
the control diet.  
Dice cluster analysis (optimization = 
0.42) of faecal and caecal DGGE 
profiles of mice fed 10% FOS (A), 
10% XOS (B) or the control diet (C). 
Faecal samples were collected on the 
day prior to onset of the feeding trial 
(start), after 3 weeks of feeding mice 
the experimental diets (before 
challenge, BC) and on Day 4 after S. 
Typhimurium SL1344 challenge (after 
challenge, AC). Caecal samples were 
collected at euthanization on Day 5 
after Salmonella challenge.  
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1 
Figure 2. Comparison of 
DGGE profiles from FOS, 
XOS or control-fed mice.  
Dice cluster analysis 
(optimisation = 0.42)  of 
DGGE profiles of A) faecal 
samples collected before 
challenge (BC); B) faecal 
samples collected on Day 4 
after S. Typhimurium SL1344 
challenge (AC); C) caecal 
samples collected at 
euthanization on Day 5 after 
Salmonella challenge. 
Arrows indicate band classes 
present in BC and AC 
profiles from FOS or XOS 
fed mice, but absent or weak 
in start profiles and profiles 
from the control group.  
A 
B 
C 
1 2 3 
2 3 
Manuscript II 
 48 
Real-time PCR analysis of the faecal and caecal microbiota  
Real-time PCR was performed to study quantitative changes in the faecal and caecal 
microbiota induced by the experimental diets and by Salmonella challenge. Within the control 
group, comparison of faecal samples collected before challenge (BC) and after challenge 
(AC) with start samples demonstrated that only the Clostridium coccoides group was changed 
over time. Compared to start samples set to 100, the C. coccoides group was reduced to 
44.6±9.0 (mean±SEM) in BC samples (P=0.0128) (Figure 3A).  
 
The prevalence of bacteria belonging to the Bacteriodetes phylum or to the Bacteroides 
fragilis group was significantly increased in faecal samples from mice fed FOS or XOS. 
Compared to start samples set to 100, the Bacteriodetes phylum was increased approximately 
2-fold by FOS feeding (BC: 237.3±33.9, P<0.0001; AC: 202.3±36.3, P=0.0034), while the B. 
fragilis group was increased from 2.5- to 3-fold (BC: 289.8±23.8; AC: 263.7±29.1; both 
P<0.0001). XOS feeding increased the Bacteriodetes phylum approximately 2-fold in BC 
samples (195.4±21.5, P=0.0473) and the B. fragilis group by 3- to 4-fold (BC: 406.9±29.2, 
P<0.0001; AC: 292.5±77.8, P=0.0032) (Figure 3A).   
 
The prevalence of bacteria belonging to the Firmicutes phylum or the C. coccoides group was 
significantly reduced in faeces by FOS or XOS feeding (Figure 3A). Compared to start 
samples set to 100, FOS feeding reduced both groups by approximately 2-fold (Firmicutes: 
BC 47.6±9.0; AC 41.1±5.3, both P<0.0001; C. coccoides group: BC 52.1±15.0, P=0.0038; 
AC 40.4±7.8, P=0.0004). XOS feeding reduced Firmicutes by approximately 2-fold (BC: 
44.0±11.4, P=0.0012; AC: 44.0±14.7, P=0.0019) and the C. coccoides group by 3- to 6-fold 
(BC: 16.1±4.1, P=0.0002; AC: 32.7±18.0, P=0.0028) (Figure 3A).  
 
The abundance of Bifidobacterium spp. in faecal samples was markedly increased by FOS 
and XOS feeding. Compared to start samples set to 100, a more than 100-fold induction in 
Bifidobacterium was seen for mice fed FOS (BC 13613.7±3952.7, P=0.0291; AC 
16694.8±6675.8 P=0.0079). The bifidogenic effect of XOS was even stronger. Compared to 
start samples set to 100, XOS increased the abundance of faecal Bifidobacterium by 
approximately 800-fold (BC 83115.6±17728.8, P<0.0001; AC 76544.9±27556.3, P=0.0001), 
which was up to 6-fold more than observed for FOS (BC P=0.0038; AC P=0.0445) (Figure 
3B). The levels of Lactobacillus spp. were unaffected in all groups (data not shown).  
No significant differences were detected between BC and AC samples in any of the groups 
demonstrating that Salmonella infection did not affect the abundance of the studied bacterial 
groups. Analysis of the caecal samples collected at euthanization on Day 5 after Salmonella 
challenge revealed that only the B. fragilis group in mice fed FOS was significantly affected 
by the dietary changes. Compared to the control group set to 100 the abundance of the B. 
fragilis group in the caecum of FOS fed animals was increased to 243.0±40.1 (P=0.0212) 
(data not shown). 
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Figure 3. Changes in bacterial groups in faecal samples analysed by real-time PCR. Real-time PCR analysis 
of faecal samples collected after 3 weeks of feeding mice the experimental diets (before challenge, BC) and on 
Day 4 after S. Typhimurium SL1344 challenge (after challenge, AC) compared to start samples set to 100. A) 
Changes in the Bacteroidetes phylum, the Bacteroides fragilis group, the Firmicutes phylum and the Clostridium 
coccoides group. B) Changes in Bifidobacterium spp. Changes in bacterial groups are presented as mean±SEM. 
*P<0.05; **P<0.01; ***P<0.001.  
 
Effects of diets on caecal SCFA concentrations 
Of the three fatty acids measured, the caecal SCFA concentrations were dominated by acetic 
acid followed by propionic and butyric acid. The concentrations of acetic acid, propionic acid 
and butyric acid were (mean±SEM) 59.1±5.6, 9.3±0.8, 6.4±1.4 mM in control mice, 50.6±8.9, 
12.9±2.4, 4.3±1.3 mM in FOS fed mice, and 60.7±24.5, 13.5±3.5, 4.4±0.8 mM in XOS fed 
mice, respectively. Consumption of FOS and XOS had no significant effect on the 
concentration of the three acids measured.   
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Discussion 
In the present study we report how diets supplemented with 10% FOS or 10% XOS affect the 
faecal and caecal microbiota of mice challenged with Salmonella. We have previously shown 
that FOS or XOS supplemented diets impair the resistance of mice to Salmonella infection 
resulting in significantly higher numbers of Salmonella in the liver, spleen and mesenteric 
lymph nodes, as well as increased levels of acute-phase proteins in the blood when compared 
to a control group (Petersen et al., 2009). In the present study, DGGE, real-time PCR and 
SCFA analyses were performed on samples collected from the same mice.  
DGGE analysis revealed that both FOS and XOS consumption induced changes in the faecal 
microbiota compared to either start samples (Figure 1A and 1B) or control animals (Figure 
2A and 2B). In contrast, caecal profiles were not different from control animals (Figure 2C). 
Our data thus suggests, that changes induced by FOS or XOS fermentation are more 
pronounced in faeces than in the caecum. Consumption of the control diet did not induce 
changes in the DGGE profiles generated from faecal samples. However, the caecal profiles 
from control-fed animals clustered separately from the faecal profiles (Figure 1C). This is in 
agreement with other studies showing that the caecal microbiota differs from the microbiota 
of faecal samples (Marteau et al., 2001).  
In faecal samples a significant increase in bacteria belonging to the Bacteroidetes phylum and 
the B. fragilis group was recorded by real-time PCR for mice fed FOS or XOS compared to 
start samples - with the sole exception of Bacteroidetes in AC samples from the XOS group 
(Figure 3A). This is in agreement with the DGGE profiling showing prominent bands 
representing Bacteroides spp. in the XOS and FOS groups. Bacteroides spp. have been 
described as the most numerous and versatile polysaccharide utilizers in the colon and have 
been shown to degrade a variety of plant oligo- and polysaccharides (Gibson and Roberfroid, 
1995; Salyers et al., 1977; Van Laere et al., 2000). Furthermore, the genome of Bacteroides 
thetaiotaomicron, isolated from human faeces, encodes several glycosylhydrolases including 
ß-fructofuranosidases involved in the breakdown of fructo-oligosaccharides (Xu et al., 2003) 
and Bacteroides spp. have been shown, at least to some extent, to ferment FOS in vitro (Van 
Laere et al., 2000).  In addition, in vitro studies have demonstrated growth of Bacteroides spp. 
on XOS (Crittenden et al., 2002; Jaskari et al., 1998; Van Laere et al., 2000). However, 
utilization of XOS by Bacteroides was less efficient compared to bifidobacteria in the study 
by Jaskari et al. (1998).  
Bifidobacterium spp. were markedly increased in the faecal microbiota by feeding on both 
FOS or XOS. However, the increase was larger for the XOS group compared to the group fed 
FOS (Figure 3B). The observed bifidogenic effect is consistent with results from other studies 
on the effect of FOS and XOS on the gut microbiota of mice (Santos et al., 2006) and rats 
(Campbell et al., 1997; Hsu et al., 2004). Furthermore, β-fructofuranosidases involved in the 
breakdown of FOS have been identified in several species of bifidobaceria (Janer et al., 2004; 
Ryan et al., 2005; Schell et al., 2002; Warchol et al., 2002) and growth of mono-cultures of 
bifidobacteria on both FOS and XOS have been demonstrated in vitro (Crittenden et al., 2002; 
Jaskari et al., 1998; Van Laere et al., 2000). A selective stimulation of bifidobacteria is one of 
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the claimed health benefits of prebiotic consumption and is believed to play an important role 
in maintaining colonization resistance and inhibition of growth of intestinal pathogens 
(Gibson et al., 2005; Gibson and Roberfroid, 1995). However, the bifidogenic effect observed 
for FOS and XOS in the present study obviously did not result in protection against the 
Salmonella infection.  
The lack of effect on Lactobacillus spp. reported within this paper is in agreement with the 
study by Campbell et al. (1997), where FOS and XOS were found to have no effect on either 
faecal and caecal numbers of Lactobacillus in rats. In vitro, XOS was found not to support the 
growth of Lactobacillus spp. in the study by Jaskari et al. (1998), whereas only a limited 
growth of Lactobacillus spp. on FOS and XOS has been reported in other in vitro studies 
(Crittenden et al., 2002; Van Laere et al., 2000).  
Concentrations of bacteria belonging to the Firmicutes phylum and the C. coccoides group 
were significantly reduced in faeces by both FOS and XOS feeding (Figure 3A). This 
reduction and the increase in Bacteroidetes and the B. fragilis group demonstrate comparable 
effects of FOS and XOS fermentation, as also observed in the DGGE analysis. In the caecal 
samples, only the B. fragilis group was significantly increased in the FOS group supporting 
the lack of clustering in DGGE profiles from the caecum (Figure 2C).  
None of the dietary interventions had any effect on the concentration of short chain fatty acids 
in the caeca of the mice. In this context it should be noted that a reduction in the C. coccoides 
group, comprising important butyrate producing strains (Louis and Flint, 2009), was observed 
in faecal samples but not in the caecum. Thus, differences in the infection susceptibility can 
not be explained by differences in butyrate levels. In a series of studies reporting adverse 
effects of FOS on S. enteritidis infections in rats (Bovee-Oudenhoven et al., 2003; Ten 
Bruggencate et al., 2003; Ten Bruggencate et al., 2005) production of lactic acid and other 
short chain fatty acids were hypothesised to cause the increased translocation of Salmonella. 
Since no increase in SCFA production was reported in this study our results do not support 
the hypothesis.  
We speculate that the observed reduction in the Firmicutes phylum and the C. coccoides 
group in faecal samples may partly explain the reduced resistance to the Salmonella infection 
as seen for FOS or XOS fed mice. The C. coccoides group constitutes a significant part of the 
Firmicutes phylum in mice (Ley et al., 2005) and are considered to be important for colonic 
health due to the production of butyrate (Louis and Flint, 2009). However, it should be noted 
that changes in the colonic microbiota might only have limited effects on the Salmonella 
infection since M cells located in the ileal Peyer’s patches are believed to be the primary site 
of pathogen translocation (Santos et al., 2003). On the other hand, alternative routes of 
intestinal translocation of Salmonella have been described, suggesting enterocytes as potential 
targets for invasion (van Asten et al., 2005) as well as uptake of the pathogen from the gut 
lumen by CD18-expressing phagocytes (Vazquez-Torres et al., 1999). Furthermore, 
Salmonella infection in rats has been shown to affect colonic mucosal gene expression, 
suggesting that both the ileum and colon are targets for Salmonella invasion (Rodenburg et 
al., 2007).  
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In conclusion, results from our study suggest that previously published adverse effects of FOS 
and XOS on Salmonella infections in mice (Petersen et al., 2009) might be associated with 
diet-induced changes in the intestinal microbiota and even though a significant bifidogenic 
effect was seen, a protective effect against Salmonella infection was not observed. We 
conclude that while bifidobacteria may have beneficial effects on some aspects of colonic 
health (Gibson and Roberfroid, 1995), a similar beneficial effect against intestinal infections 
does not necessarily occur. 
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Abstract 
Diets high in meat, but low in fibre, have been associated with increased risk of developing colon 
cancer, while a reduced risk has been linked to diets high in fibre. Studies in rats also show that dietary 
fibre as resistant starch can attenuate colonic DNA damage induced by high levels of dietary protein, 
including a soy protein isolate. In the present study, we examine whether xylo-oligosaccharides (XOS) 
can reduce protein-induced faecal water genotoxicity. Substrates were fermented in vitro by a human 
faecal microbiota using a two-stage continuous fermenter simulating the conditions of the proximal 
colon (vessel 1, pH 5.5) and of the distal colon (vessel 2, pH 6.8). As an inducer of genetic damage 
3% soy protein was added to a basal media along with either 1% cornstarch or 1% XOS. Ten days of 
cornstarch fermentation with soy protein followed by ten days of XOS fermentation with soy protein 
significantly reduced faecal water genotoxicity in vessel 1, while an increased genotoxicity was 
observed for vessel 2. In both vessels XOS fermentation significantly increased the average butyrate 
concentration. Relative to cornstarch fermentation XOS increased numbers of the Clostridium 
coccoides group in both vessels. Furthermore, the Bacteroides fragilis group, Lactobacillus spp. and 
sulphate-reducing bacteria (SRB) were increased in vessel 1. In both vessels a reduction in 
Faecalibacterium prausnitzii was observed in addition to reductions in Bifidobacterium spp., the 
Clostridium leptum group and SRB in vessel 2. Based on these results XOS fermentation is capable of 
stimulating butyrate producing bacteria (the C. coccoides group), to increase butyrate concentrations 
and to alter protein-induced faecal water genotoxicity with a potential to protect against genetic 
damage in the proximal colon. 
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Introduction 
During recent years there has been a considerable interest in dietary components that can 
modulate the gut microbiota and potentially improve gut health [1]. In this regard the concept 
of prebiotic carbohydrates has been developed to selectively stimulate the growth and activity 
of beneficial bacteria (predominately bifidobacteria and lactobacilli) in the intestinal tract 
[2,3]. The most well studied prebiotics are inulin and fructo-oligosaccharides (FOS), while 
xylo-oligosaccharides (XOS) are considered as promising prebiotic candidates [3,4]. XOS 
oligomeres are composed of xylose units linked by ß-1.4 linkages [5,6]. Due to their ß-
configuration the oligomeres are not degraded by human digestive enzymes and reach the 
large intestine chemically intact, where they act as a substrate for the colonic microbiota [6]. 
XOS has been shown to support the growth of several species of bifidobacteria in in vitro 
mono-cultures [7,8] and in mixed cultures [9-11]. In vivo, studies have demonstrated a 
bifidogenic effect in rats [12,13] and humans [14]. Effects on lactobacilli are more diverse 
with some in vitro and in vivo studies reporting no significant change in this bacterial genus 
[7,9,11,12],  while others report growth of at least some Lactobacillus spp. on XOS [8,10,15]. 
Several health-benefits of prebiotic consumption have been postulated including a potential 
reduced risk of colon cancer [16,17]. The possibility of dietary modification of colon cancer 
risk have been investigated by Hsu et al. [13] by administration of XOS and FOS to 1,2-
dimethylhydrazine (DMH) treated rats. In the study both prebiotics reduced numbers of pre-
cancerous lesions (aberrant crypt foci) in the distal colon, with the largest reduction observed 
for XOS.  
Epidemiological studies indicate that the risk of developing colon cancer is increased by 
consumption of high-protein diets [18-20]. In contrast, consumption of complex 
carbohydrates may provide protection against development of colon cancer [5,21-27]. 
Mechanisms responsible for the protective effect include reduced transit time, as a result of 
increased bacterial biomass and hence increased stool frequency [28], increased short chain 
fatty acid (SCFA) production, in particular butyrate [29,30], and changes in the microbial 
composition towards primarily saccharolytic bacteria (eg. bifidobacteria and lactobacilli) [16].  
Butyrate is the preferred energy source for colonic epithelial cells [31], and is believed to be 
an important mediator of the protective effect of dietary fibres against colon cancer 
[23,32,33]. From in vitro studies proposed mechanisms responsible for the anti-carcinogenic 
effect of butyrate is induction of cell cycle arrest and apoptosis in cancer cells promoting a 
normal phenotype of colonocytes [34-37].  
Using a continuous two-stage fermenter system the aim of the present study was to investigate 
the genotoxic potential of faecal water from XOS fermentation using the comet assay to 
elucidate whether protein-induced genetic damage on human HT-29 colonocytes could be 
reduced by fermentation of XOS as compared to cornstarch, and to relate these changes to the 
effect of XOS fermentation on the composition of a human faecal microbiota and SCFA 
production. 
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Materials and Methods 
Faecal inoculum 
Faecal samples from five healthy adult volunteers, who had not received antibiotics or 
experienced episodes of diarrhoea for 4 weeks prior to the study, were collected and kept on 
ice at 5 ºC in airtight plastic bags until use (a maximum of two hours on ice was allowed). In 
an anaerobic chamber samples were homogenized, pooled and diluted in anaerobic PBS (0.1 
M, pH 7.2) to produce a 20% (w/v) faecal slurry. The slurry was prepared just prior to 
inoculation of the fermenter. 
 
Fermentation media 
The fermentation study was preformed using a basal media prepared according to Bruck et al. 
[38] with minor changes: NaCl (0.05 g/L, Sigma-Aldrich), K2HPO4 (0.02 g/L, BDH 
Laboratory Supplies), KH2PO (0.02 g/L, Ajax Finechem), MgSO4·7H2O (0.005 g/L, Sigma-
Aldrich), CaCl2·2H2O (0.0034 g/L, BDH Laboratory Supplies), NaHCO3 (1 g/L, Sigma-
Aldrich), haemin (0.0025 g/L, Sigma-Aldrich), Cystein HCL (0.25 g/L, Sigma-Aldrich), bile 
salts (0.25 g/L, Oxoid), Tween 80 (1 ml/L, Sigma-Aldrich) and vitamin K1 (5 μl/L, Sigma-
Aldrich). The media was prepared in 10x stock solutions with pH adjusted to 7.0, sterilized by 
autoclaving at 121 ºC for 20 min. and kept at 5 ºC. Media, ready for use in the fermenter, was 
prepared from stocks in a volume of 3 L just prior to connecting the media reservoir to the 
fermenter. As an inducer of DNA damage the media was supplemented with 3% (wt/v) soy 
protein (Morlife Pty. Ltd., Labrador, Australia) previously shown to induce DNA damage in 
vivo [24]. Carbohydrate sources were 1% (wt/v) of either a highly digestible low amylose 
cornstarch (3401C, The National Starch and Chemical Company, Australia) or xylo-
oligosacharides (XOS), DP 2-6 (Danisco Health & Nutrition, Kantvik, Finland). 
 
Two- stage continuous fermenter system  
The fermenter was set up as described by Bruck et al. [38] with minor changes. The fermenter 
consisted of two glass vessels, vessel 1 (V1) and vessel 2 (V2), with an operating volume of 
220 ml and 320 ml, respectively. Vessel temperature was kept at 37 ºC and pH was 
automatically controlled with 0.1 M NaOH. V1’s pH was kept at 5.5, representing the low pH 
environment of the proximal colon and 6.8 in V2, representing the more neutral pH in the 
distal colon. Both vessels and media reservoir were magnetically stirred and kept anaerobic 
by continuous gassing with sterile filtered oxygen-free nitrogen.    
The fermenter was set up on the day prior to inoculation (Day -1). Basal media supplemented 
with 3% soy protein and 1% cornstarch was added to each vessel to allow the temperature to 
reach 37 ºC and anaerobic conditions to develop. On the following day (Day 0) the faecal 
slurry was added to the vessels to a final concentration of 2% and the first sample (7 ml) was 
taken. On Day 1 the media reservoir and the pump were connected to V1 with a flow rate of 
0.03 L/hour (total transit time of 18 hours). V1 subsequently supplied V2. Samples (7 ml) 
were taken daily in the morning from each vessel and kept at -80 ºC until further analysis. The 
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media reservoir was changed every third day with cornstarch as the carbohydrate source for 
the first 10 days (Days 1-10) followed by 10 days with XOS fermentation (Days 11-20).  
 
Growth and maintenance of HT29 cells 
Human HT29 colonocytes were cultured in Dulbecco’s Modified Eagel Medium (DMEM) 
supplemented with 10% fetal bovine serum, 0.37% NaHCO3, 0.60% HEPES (Sigma-Aldrich) 
and 1% Antibiotic/Antimycotic at 37 ºC in an atmosphere of 5% CO2. All chemicals were 
from Invitrogen unless otherwise stated. pH of the media was adjusted to 7.3. Cells were 
grown in 20 ml supplemented DMEM in 75 cm
3
 tissue culture flasks (Grenier Bio-One) and 
passaged once weekly with cells being ~90% confluent.  
 
Faecal water assay 
Faecal water was isolated from samples collected on Days 8, 9 and 10 (cornstarch) and Days 
18, 19 and 20 (XOS) from vessel 1 and 2 by centrifugation at 2000 g for 45 min, 4 ºC and 
stored at -80 ºC. HT29 cells were treated with a homogenous sample of faecal water from 
Days 8-10 or Days 18-20. Media from a flask of ~90% confluent HT29 cells was carefully 
removed. Cells were washed twice in 10 ml pre-warm (37 ºC) PBS and incubated with 1 ml 
Trypsin-EDTA (Invitrogen) for 5 min. at 37 ºC, 5% CO2. Cells were disaggregated in 10 ml 
pre-warm (37 ºC) supplemented DMEM, counted and diluted to a concentration of ~8.500 
cells/ml. Cell suspensions (2 ml/well) were added to 6-well tissue culture plates (BD 
Biosciences) and incubated overnight at 37 ºC, 5% CO2. 
For treatment of cells with faecal water a 20% dilution in PBS was chosen based on comet 
assays performed with 0.1-100% faecal water. Media was removed from cells growing 
overnight and cells were washed twice in 1 ml PBS. Faecal water (1 ml) was added to each 
well and cells were incubated for 30 min. at 37 ºC, 5% CO2. Control cells were incubated 
with 1 ml 50 μM H2O2 (positive control) (Sigma-Aldrich) and with 1 ml PBS (negative 
control). After 30 min. solutions were removed and cells were washed twice in 1 ml PBS. 
Trypsin-EDTA (100 μl) was added to each well and plates were incubated for 5 min. at 37 ºC, 
5% CO2. Pre-warm supplemented DMEM (2 ml) was added to each well and cells were 
carefully disaggregated. From each well 500 μl aliquots were transferred to microcentrifuge 
tubes, and centrifuged at 4000 rpm for 5 min. Media was discharged and cells were used for 
the comet assay. Trypan blue was added to 20 μl cell suspension from each well to determine 
the viability of cells. 
 
Comet assay 
Single-strand DNA breaks induced by the faecal water treatments were investigated using the 
single-cell gel electrophoresis assay (comet assay) [39,40]. Cells isolated from the faecal 
water assay were resuspended in 200 μl pre-warm low melting agarose (LMA) (Trevigen) and 
45 μl were pipetted onto the 1st well of two comet assay glass slides (Trevigen). Another 45 μl 
LMA was added to the remaining cells, mixed briefly and 45 μl were pipetted onto the 2nd 
well of the two slides. The cell suspension was spread evenly across the surface of the glass 
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slide, covered with a cover slip and kept on ice for 30 min. to allow the agarose to solidify. 
The cover slips were removed and the slides were immersed in a cold lysis buffer (Trevigen) 
at 4 ºC for 1 hour. Slides were placed in an electrophoresis tank containing alkaline 
electrophoresis buffer (300 mM NaOH, 1 mM Na2EDTA, pH>13) kept at 4 ºC. Slides were 
submerged in the buffer for 20 min. before electrophoresis were conducted at 25 V, 300 mM 
for 20 min. Slides were removed from the alkaline buffer and placed in a pH neutralizing 
buffer (400 mM Tris-HCl, pH 7.5) for 3x5 min., fixed in 96% ethanol for 5 min. and left to 
dry at 37 ºC for 5 min. Slides were stained with propidium iodide (Sigma-Aldrich) and 
images were captured using an Olympus BX-41 fluorescent microscope and the software 
Image Pro Plus (Media Cybernetics Inc.). Tail length, % DNA in tail and comet tail moment 
(the product of tail length and the fraction of DNA in the tail) were calculated for ~50 cells pr. 
slide using CometScore™ v1.5 (TriTek Corp.). Apoptotic cells were excluded from the 
analysis based on their morphology.  
 
SCFA analysis 
Fermentation samples (1 ml) from Days 1-20 were diluted 1:3 in an internal standard (1.68 
mM Heptanoic acid, pH 7) and left for sedimentation of particulate material. Supernatants 
(150 μl) were distilled by vacuum distillation as described by Patten et al. [41]. Distillates (60 
μl) were analysed for total acids and SCFAs (acetate, butyrate and propionate), in duplicates, 
using Agilent Technologies 6890N Network Gas Chromatograph System fitted with a Zebron 
ZB-FFAP capillary GC column (Dimension: 30m x 0.53mm I.D) (Phenomenex) as previously 
described by McOrist et al. [42]. A standard mixture of acetic, propionic, isobutyric, butyric, 
isovaleric, valeric, caproic and heptanoic acids was used to calibrate the GC.  
 
DNA extraction and quantification 
DNA was extracted from 0.5 ml of the fermentation samples collected on Days 8-10 
(cornstarch) and Days 18-20 (XOS). Samples were centrifuged at 13.000 g for 5 min. and 
pellets were resuspended in 1.2 ml TE Buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8) and 
transferred to 2 ml microcentrifuge tubes containing 0.5 ml zirconia-silica beads (0.1 mm, 
Biospec Products) and 30 μl 10% SDS. Bacteria cells were lysed by shaking for 5 min. on a 
minibead beater on high speed and centrifuged at 4500 g for 1 min. DNA was extracted from 
supernatants using the QIAamp DNA Stool Mini Kit (Quiagen) according to the 
manufacturer’s instructions and stored at -20 ºC until use. DNA concentrations were 
quantified using Quanti-iT Pico Green (Invitrogen) with fluorescence measured using a PTC-
200 Peltier Thermal Cycler (MJ Research).  
 
Real-time PCR 
Real-time PCR was performed on DNA extracted from fermentation samples collected on 
Days 8-10 (cornstarch) and Days 18-20 (XOS). Primers and amplification conditions for 
quantification of specific bacterial groups and species are listed in Table 1 and Table 2. All 
reactions were performed in 10 μl reactions with 1 μl template DNA, except Akkermansia 
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municiphila and sulphate-reducing bacteria. For these assays 3 μl template DNA was used in 
a 20 μl reaction. Each reaction contained template DNA, Ssofast Evagreen Supermix (2x) 
(Bio-Rad), primers (Table 1), 0.4 μl BSA (Promega) or 1 μl Dimethyl Sulfoxide (sulfate-
reducing bacteria only) (Sigma-Aldrich) and Milli-Q to a final volume of 10 or 20 μl. Each 
sample was analysed in triplicates per PCR run. Amplifications were performed with an initial 
denaturation at 98 ºC for 2 min. followed by 35-40 cycles of 98 ºC for 5 sec., 52-65 ºC for 15-
60 sec. and 72 ºC for 30-45 sec (Table 2). A final melting-curve analysis was performed after 
completion of all cycles with fluorescence collected at 0.5-1 ºC intervals between 55 and 95 
ºC. A series of 10-fold dilutions of control template were analysed in parallel with the 
fermentation samples. All reactions were run on a PTC-200 Peltier Thermal Cycler (MJ 
Research) and analysed using MJ Opticon Monitor Analysis Software Version 3.1 (Bio-Rad) 
and qBase (Biogazelle). In order to correct data for differences in total DNA concentrations 
between samples results were analysed relative to total bacterial amplification.  
 
Table 1. Primers used for real-time PCR assays 
Target Primer Sequence (5’-3’) nM Reference 
Total bacteria 
1114F 
1275R 
CGGCAACGAGCGCAACCC 
CCATTGTAGCACGTGTGTAGCC 
150  [43] 
Akkermansia municiphila 
AM1 
AM2 
CAGCACGTGAAGGTGGGGAC 
CCTTGCGGTTGGCTTCAGAT 
350 [44] 
Bacteroides fragilis group 
Bfr-F 
Bfr-R 
CTGAACCAGCCAAGTAGCG 
CCGCAAACTTTCACAACTGACTTA 
500 [45] 
Bifidobacterium spp. 
Bif-F 
Bif-R 
TCGCGTC(C/T)GGTGTGAAAG 
CCACATCCAGC(A/G)TCCAC 
600 [46] 
Clostridium coccoides group 
g-Ccoc-F 
g-Ccoc-R 
AAATGACGGTACCTGACTAA 
CTTTGAGTTTCATTCTTGCGA A 
250 [47] 
Clostridium leptum group 
sg-Clept-F 
sg-Clept-R 
CTTTGAGTTTCATTCTTGCGAA 
GCACAAGCAGTGGAGT 
250 [47] 
Escherichia coli 
E.coli F 
E.coli R 
CATGCCGCGTGTATGAAGAA 
CGGGTAACGTCAATGAGCAAA 
375 [48] 
Faecalibacterium praunitzii 
FPR-1F 
FPR-2R 
AGATGGCCTCGCGTCCGA 
CCGAAGACCTTCTTCCTCC 
500 [49] 
Lactobacillus group 
Lacto-F 
Lacto-R 
AGCAGTAGGGAATCTTCCA 
CACCGCTACACATGGAG 
500 
[46] 
 
SRB
1
_aps
2
 
APS3F 
APS2R 
TGGCAGATCATGWTYAAYGG 
GGGCCGTAACCRTCYTTRAA 
400 
Modified 
from [50] 
SRB_dsr
3
 
DSR1F+ 
DSR-R 
ACSCACTGGAAGCACGGCGG 
GTGGMRCCGTGCAKRTTGG 
400 [51] 
Desulfovibrio spp (SRB) 
DSV691-F 
DSV826-R 
CCGTAGATATCTGGAGGAACATCAG 
ACATCTAGCATCCATCGTTTACAGC 
300 [52] 
1
Sulfate-reducing bacteria, 
2
Adenosine-5-phosphosulfate reductase gene, 
3
Dissimilatory sulfite reductase gene. 
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Table 2. Amplification conditions for real-time PCR assays 
Target Annealing Elongation 
 ºC Time (sec.) ºC Time (sec.) 
Total bacteria  60 20 72 45 
Akkermansia municiphila 63 30 72 30 
Bacteroides fragilis group 58 60 72 30 
Bifidobacterium spp.  58 20 72 30 
Clostridium coccoides group  58 20 72 45 
Clostridium leptum group 58 20 72 45 
Escherichia coli  60 20 72 45 
Faecalibacterium praunitzii 62 20 72 40 
Lactobacillus group 58 30 72 30 
SRB_aps 58 30 72 60 
SRB_dsr 65 15 72 30 
Desulfovibrio spp. (SRB) 62 30 72 30 
 
Statistics 
Data was tested for normal distribution using the Shapiro-Wilk test. Normal distributed data 
was analysed using a two-way analysis of variance (ANOVA) with fermenter and 
carbohydrate as variables. Where ANOVA indicated a significant difference Student’s t-test 
was used to compare means of treatments. Data that did not meet the criteria of normal 
distribution was analysed using the non-parametric Kruskal-Wallis test. All statistical 
analyses were carried out using SAS JMP version 7. P values of <0.05 were considered 
statistically significant.  
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Results  
Faecal water genotoxicity  
Viability of the HT29 cells used for the comet assay was assessed by the trypan blue 
exclusion method and was shown to be greater than 95% (data not shown). Single-stranded 
DNA breaks were assessed by the comet assay performed with a homogenous sample of 
faecal water from Days 8-10 (cornstarch) or Days 18-20 (XOS). Results are presented as tail 
length, % DNA in the tail and tail moment (Table 3).  
 
Table 3. Genetic damage induced by faecal water samples from fermentation of cornstarch or XOS 
DNA damage (arbitrary units) 
Vessel Carbohydrate  Tail length % DNA in tail Tail moment 
V1 (pH 5.5) Cornstarch, Days 8-10 44.08±2.94
b
 14.71±0.85
bc
 7.62±0.74
b
 
 XOS, Days 18-20 33.32±2.36
c
 13.98±0.62
c
 5.37±0.51
c
 
V2 (pH 6.8) Cornstarch, Days 8-10 34.54±2.04
c
 16.51±0.79
ab
 6.70±0.56
bc
 
 XOS, Days 18-20 62.01±3.77
a
 17.82±0.79
a
 12.79±1.01
a
 
Values (mean±SEM) within each column with unlike superscript letters were significantly different (P<0.05).  
 
Results from the comet assay revealed differences in the effect of XOS fermentation on the 
genotoxicity of faecal water samples from the two vessels. In vessel 1, tail length (P=0.0097) 
and tail moment (P=0.0293) was reduced by XOS fermentation indicating a protective effect 
of XOS against protein-induced genetic damage. In contrast, an increase in tail length and tail 
moment was observed in vessel 2, both P<0.0001. No significant effect on % DNA in the tail 
was observed within the vessels. 
 
Short chain fatty acids 
SCFA production confirmed the occurrence of bacterial fermentation in both vessels. The 
average concentration of total acids and SCFAs was significantly higher in vessel 2 compared 
to vessel 1 (P<0.0001), indicating a higher level of fermentation in vessel 2 (Table 4). In 
vessel 1, the average concentration of acetate from fermentation of cornstarch (Days 1-10) 
was significantly higher relative to XOS fermentation (Days 11-20) (P=0.0411). In contrast, 
the concentration of propionate was increased by XOS (P=0.0284) in vessel 1. In both 
vessels, the average concentration of butyrate was significantly increase by XOS fermentation 
compared to fermentation of cornstarch (V1: P=0.0186, V2: P<0.0001). 
 
Table 4. Average SCFA concentration from fermentation of cornstarch or XOS 
Average SCFA concentration (mM) 
Vessel Carbohydrate  Acetate Butyrate Propionate Total acids 
V1 (pH 5.5) Cornstarch, Days 1-10 71.6±11.1
b
 15.6±5.0
d
 2.5±2.0
c
 90.4±13.5
b
 
XOS, Days 11-20 62.4±18.4
c
 22.5±8.4
c
 2.8±1.5
b
 88.3±22.4
b
 
V2 (pH 6.8) Cornstarch, Days 1-10 107.0±15.8
a
 34.5±6.8
b
 24.7±10.5
a
 181.8±37.9
a
 
XOS, Days 11-20 99.0±7.8
a
 44.7±5.8
a
 27.2±6.2
a
 179.0±13.3
a
 
Values (mean±SD) within each column with unlike superscript letters were significantly different (P<0.05). 
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Changes in bacterial population induced by XOS fermentation 
Among the analysed bacterial groups only the C. coccoides group was significantly 
stimulated by XOS fermentation in both vessels relative to cornstarch fermentation (V1: 
P=0.015; V2: P=0.007) (Table 5). Furthermore, the B. fragilis group (P=0.024), Lactobacillus 
spp. (P=0.042) and sulphate-reducing bacteria (SRB) (aps: P=0.004; dsr: P=0.008; 
Desulfovibrio spp. P=0.015) were increased in vessel 1. Bacterial groups reduced by XOS 
fermentation were F. prausnitzii in both vessels (V1: P=0.001; V2: P=0.003) as well as 
Bifidobacterium spp. (P=0.01), the C. leptum group (P=0.001), SRB_aps (P=0.039) and 
SRB_dsr (P=0.018) in vessel 2. Levels of Akkermansia municiphila and E. coli were 
unaffected by the change in carbohydrate in both vessels. 
 
Table 5. Relative quantification of specific bacterial groups from fermentation of cornstarch or XOS 
Bacterial group Vessel 1 (pH 5.5) Vessel 2 (pH 6.8) 
 Cornstarch 
Days 8-10 
XOS 
Days 18-20 
Cornstarch 
Days 8-10 
XOS 
Days 18-20 
A. municiphila 0.028±0.042 0.018±0.010 0.013±0.009 0.008±0.003 
B. fragilis group 0.014±0.009
b
 0.524±0.344
a
 6.437±0.968 7.045±0.641 
Bifidobacterium spp. 0.638±0.111 0.671±0.127 1.019±0.285
a
 0.338±0.082
b
 
C. coccoides group 0.739±0.252
b
 4.268±1.845
a
 0.936±0.403
b
 2.597±0.278
a
 
C. leptum group 0.065±0.008 0.116±0.055 1.087±0.103
a
 0.433±0.054
b
 
E. coli 0.006±0.005 0.289±0.400 0.025±0.025 0.053±0.026 
F. prausnitzii 0.468±0.067
a
 0.119±0.026
b
 1.004±0.284
a
 0.179±0.065
b
 
Lactobacillus spp. 0.059±0.019
b
 0.122±0.032
a
 0.029±0.007 0.023±0.003 
SRB
2
_aps
3
 0.014±0.007
b
 0.281±0.122
a
 0.626±0.220
a
 0.301±0.019
b
 
SRB_dsr
4 
0.009±0.009
b
 0.348±0.184
a
 0.806±0.309
a
 0.218±0.055
b
 
Desulfovibrio spp. (SRB) 0.012±0.007
b
 0.429± 0.297
a
 2.469± 0.672 1.531±0.468 
1
Values (mean±SD) were calculated relative to total bacteria. From each vessel, values within each row with 
unlike superscript letters were significantly different (P<0.05). 
2
Sulfate-reducing bacteria, 
3
Adenosine-5-
phosphosulfate reductase gene, 
4
Dissimilatory sulfite reductase gene. 
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Discussion 
The present study investigated the effect of in vitro fermentation of XOS on the genotoxicity 
of faecal water samples, SCFA production and on the composition of a human faecal 
microbiota. XOS was selected based on its potential use as a prebiotic substrate believed to 
promote gut health via e.g. SCFA production and an altered gut microbiota.  
Differences in the genotoxic potential of faecal water samples after XOS fermentation were 
observed for the two vessels, suggesting that XOS could protect against protein-induced DNA 
damage in the colon, but that the protection is restricted to the proximal colon. Several animal 
studies have implicated dietary fibres and production of butyrate in protection against colon 
cancer [23,32,33]. In the present study a significantly elevated concentration of butyrate was 
seen for both vessels, but a reduction in genotoxicity was only observed for vessel 1. Thus, 
from our results an increased butyrate concentration is not in itself preventive against protein-
induced genetic damage.  
In humans butyrate is mainly produced by Roseburia spp. and Eubacterium rectale, both 
members of the C. coccoides group (clostridial cluster XIVa), and to a lesser extent by F. 
prausnitzii belonging to the C. leptum group (clostridial cluster IV) [53]. Hence, the increase 
in butyrate concentrations seen in the present study is consistent with the increase in the C. 
coccoides group in both vessels.  
The differences observed in the genotoxicity between the two vessels might be explained by 
XOS induced changes in the composition of the bacterial population. Both Lactobacillus spp., 
the B. fragilis group and sulphate-reducing bacteria were stimulated by XOS fermentation in 
vessel 1 (pH 5.5), but not in vessel 2 (pH 6.8). Growth of Lactobacillus on XOS have 
previously been shown in vitro [10] and a recent study from our lab demonstrated increased 
levels of the B. fragilis group in the faecal microbiota of mice fed XOS (Manuscript II). The 
increase in these bacterial groups in vessel 1 may result from the higher level of carbohydrate 
availability in this vessel compared to vessel 2. This would be consistent with in vivo 
conditions where the primary site of fermentation of non-digestible carbohydrates is the 
proximal colon [54], particularly with carbohydrates with a low degree of polymerization 
(DP) such as XOS [55]. Thus, it is possible that the reduction in faecal water genotoxicity 
observed for vessel 1, but not for vessel 2, may at least partly result from differences in the 
level of XOS fermentation between the two vessels. In vivo, a consequence of the intense 
fermentation of carbohydrates in the proximal colon is that less is available for fermentation 
in the distal colon making metabolism of proteins quantitatively more dominating [54]. In 
addition to production of SCFAs, degradation of proteins also generates potential genotoxic 
substrates such as ammonia, phenols, indoles, and amines [56,57], which may increase the 
genotoxic potential of food residues entering the distal colon. 
The role of sulphate-reducing bacteria (SRB) in gastrointestinal health is poorly understood 
[58]. In the present study an increase in SRB was observed for vessel 1 (decreased 
genotoxicity), whereas a decrease in SRB was observed for vessel 2 (increased genotoxicity). 
Our results thus indicate a positive role of SRB in the gut.  
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SRB are a diverse bacterial group of which the genus Desulfovibrio is the most common SRB 
isolated from animal and human faeces. Within the intestinal tract SRB are the terminal 
oxidizers in the anaerobic degradation of organic matter from which they reduce sulphur-
containing compounds to hydrogen sulphide (H2S) [58]. H2S produced by SRB have been 
suggested as a potential toxin to the gut epithelium [59,60] implicating SRB in the 
pathogenesis of IBD [61,62] and colon cancer [63]. In contrast, other studies have reported no 
increase in colonic Desulfovibrio spp. and no elevated faecal H2S concentration in ulcerative 
colitis patients [52,64,65]. Studies investigating the presence of faecal Desulfovibrio spp. in 
colon cancer patients either found no difference or reported a decrease (potentially caused by 
colectomy procedures) in Desulfovibrio spp. [58,66]. Thus, collectively these studies question 
the specific role of H2S and SRB in the gut.  
In a recent study by Wallace et al. [67], H2S, produced by colonic tissue, was demonstrated as 
preventive to experimentally induced colitis in rats suggesting an anti-inflammatory effect of 
H2S. Furthermore, inhibition of H2S synthesis significantly increased mortality rates of rats 
suffering from colitis [67]. From these results it is possible that also bacterial derived H2S is 
beneficial for the colonic epithelium suggesting a predominantly positive role of sulphate-
reducing bacteria in the gut as also indicated by our study.  
The present study did not demonstrate a bifidogenic effect of XOS, and in fact a decrease in 
bifidobacteria was observed for vessel 2. Other in vitro studies investigating the effect of 
XOS on the composition of a human faecal microbiota have reported an increase in 
bifidobacteria [9-11]. In vivo studies of the effect of XOS on the human gut microbiota are 
limited, but a recent study by Chung et al. [14] demonstrated a bifidogenic effect of XOS 
consumption in elderly aged ≥65. Furthermore, studies with rodents have demonstrated an 
increase in faecal and caecal numbers of bifidobacteria in response to XOS feeding [12,13]. 
Since bifidobacteria have been suggested to play a role in protection of the colonic epithelium 
[68], a reduction in this bacterial genus might increase the risk of intestinal disorders. Hence, 
the decrease in Bifidobacterium spp. as well as the decrease in SRB observed for vessel 2 may 
both be factors contributing to the increased genotoxicity. Furthermore, a reduction in F. 
prausnitzii, as observed for both vessels, may be associated with reduced protection of the gut 
mucosa, since this bacterium has been shown to exhibit anti-inflammatory effects and is 
present in low numbers in the faecal microbiota of humans suffering from inflammatory 
bowel diseases (IBD) [69,70].  
In conclusion, the present study demonstrated the ability of XOS to reduce protein-induced 
genetic damage in vessel 1, to stimulate numbers of butyrate producing bacteria (the C. 
coccoides group) as well as butyrate production. Butyrate alone was not protective against 
genetic damage induced by protein fermentation as observed for vessel 2, whereas quantities 
of some bacterial groups and species were related to changes in the genotoxicity of faecal 
water. Reductions in Bifidobacterium spp. and sulphate-reducing bacteria (SRB) were related 
to an increase in genetic damage, suggesting a potential beneficial role of SRB in gut health 
rather than relating this bacterial group to intestinal disorders as previously suggested.  
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9. SUMMARISING DISCUSSION AND CONCLUSION  
The concept of prebiotics was introduced as an approach of selectively stimulating the growth 
and/or activity of beneficial bacteria indigenously present in the intestinal tract [24,30]. The 
aim of Manuscript I was to investigate whether consumption of prebiotic dietary 
carbohydrates and other potential prebiotics could improve the resistance of mice to S. 
Typhimurium SL1344 infection. Despite studies with probiotics demonstrating protective 
effects against murine S. Typhimurium infections [78-85], such an effect was not observed for 
the carbohydrates investigated in Manuscript I. None of the carbohydrates exhibited any 
protective effect against the Salmonella infection and in fact, two of the tested carbohydrates, 
FOS and XOS, increased numbers of the pathogen in the liver, spleen and mesenteric lymph 
nodes relative to control-fed mice. In mice fed apple pectin a markedly increased number of 
the pathogen was observed in the content of the distal ileum and in faecal samples. 
Additionally, a trend, though not statistically significant (P=0.18-0.29), indicating increased 
pathogen numbers in the content of the distal ileum and faecal samples was observed for mice 
fed FOS and XOS. Similarly, a trend towards increased numbers of Salmonella in the 
investigated organs was observed for the group fed apple pectin (P=0.15-0.21). Based on 
these results the hypothesis was that a high ileal level of Salmonella was accompanied by a 
high content of the pathogen in internal organs even though this was only indicated by trends 
in our data. 
In accordance with the increased organ counts of Salmonella in mice fed FOS or XOS the 
concentration of the acute phase protein haptoglobin, measured in serum samples, was 
significantly elevated in these two dietary groups relative to infected mice fed the control diet. 
Haptoglobin is produced by the liver in response to tissue damage and inflammation with 
interleukin 6 thought to be the major regulator of the acute phase protein response [229,230]. 
Binding of free plasma haemoglobin (Hb) is generally accepted as the primary function of 
haptoglobin, whereby the host is protected against oxidative damage mediated by free Hb, 
renal damage as a result of Hb accumulation and Hb loss (and thus loss of iron) [231]. Thus, 
the increase in serum haptoglobin concentrations as well as the positive correlation between 
neutrophils in the spleen and numbers of Salmonella in the organs, but not in the distal ileum 
(Manuscript I, study C), indicate an immune response towards bacteria translocated to the 
organs rather than Salmonella present in the ileum.  
To further investigate potential explanations for the increase in pathogen translocation 
observed for FOS or XOS fed mice, changes in the faecal and caecal microbiota of these mice 
were analysed in Manuscript II. In this study, the faecal microbiota of FOS or XOS fed mice 
was seen to differ from the control group by DGGE and real-time PCR analysis. Among the 
investigated bacterial groups the changes induced by FOS or XOS were comparable and 
constituted a significant increase in the Bacteroidetes phylum, the Bacteroides fragilis group 
and in Bifidobacterium spp. in faecal samples as well as a reduction in the Firmicutes phylum 
and Clostridium coccoides group. Assuming that these changes were, at least partly, the cause 
of the increased translocation of Salmonella in FOS or XOS fed mice, changes in the large 
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intestinal microbiota can affect the pathogenesis of the pathogen even though ileal M cells are 
described as the classical route of Salmonella invasion [197]. In this context it should be 
noted that FOS-fed rats challenged with S. Enteritidis in the study by Bovee-Oudenhoven et 
al. [152] did not show sings of intestinal inflammation, measured as myeloperoxidase  
activity, in the ileal mucosa. In contrast, a significantly increased enzyme activity was 
observed for the caecal and colonic mucosa suggesting pathogen translocation through the 
large intestinal epithelium. 
Since samples from the ileum were not available for analysis in Manuscript II, it is unknown 
whether microbial changes in this part of the gut were a factor contributing to the increased 
level of translocation. However, the DGGE and real-time PCR analysis performed on faecal 
and caecal samples demonstrated that the effects of the experimental diets were largely 
restricted to the faecal microbiota, suggesting that diet-induced microbial changes in the 
ileum would be limited.  
Increased numbers of bifidobacteria are generally regarded as beneficial to gut health [30]. 
Manuscript II revealed a strong bifidogenic effect of both FOS and XOS, but this was not 
seen to provide protection against the Salmonella infection. Similar results have been 
published by Ten Bruggencate and co-workers [151,152,154], where FOS feeding of rats 
increased faecal numbers of bifidobacteria prior to S. Enteritidis infection. Despite the 
bifidogenic effect, FOS administration was seen to increase the intestinal permeability and to 
increase pathogen translocation. Thus collectively, these and our results do not support the 
assumption that increased numbers of bifidobacteria improve host resistance to infections by 
gut pathogens. Still, studies with orally applied strains of bifidobacteria (B. longum, B. lactis 
and B. breve) have demonstrated protective effects against murine Salmonella infections 
[78,81,83]. Within other areas of research related to gut health such as treatment and/or 
prevention of inflammatory bowel disease, allergies, diarrhoea and colon cancer, clinical 
investigations have shown promising results of probiotic administration of Bifidobacterium 
spp., but at present these are generally not sufficient for any final conclusions to be drawn 
[86,87,232-235].  
Among studies with prebiotics, with a demonstrated bifidogenic effect, Kleessen et al. [236] 
studied the effect of inulin and FOS on the intestinal mucosal morphology (height of villi, 
depth of crypts, number of goblet cells) and on the thickness of the epithelial mucus layer by 
comparing germ-free rats and rats colonised with a human faecal microbiota. The thickness of 
the epithelial mucus layer, villus height, crypth depth and numbers of goblet cells were higher 
in rats with a human faecal microbiota compared to germ-free rats, and the morphological 
features were significantly enhanced in these animals by the prebiotic diet. Additionally, 
numbers of mucosa-associated bifidobacteria in the distal colon were stimulated by the 
experimental diet. Together these findings suggest a role of the prebiotics in stabilizing the 
mucosal barrier of the gut and indicate that bifidobacteria are involved in protecting the 
mucosal epithelium. However, these results contradict our findings of a reduced resistance to 
the Salmonella infection, as observed in Manuscript I, despite the bifidogenic effect of both 
FOS and XOS. 
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The last study included in this thesis (Manuscript III) addressed the effect of in vitro 
fermentation of XOS on the composition of a human faecal microbiota and whether 
fermentation of this carbohydrate could provide protection against protein-induced genetic 
damage. Using a two-stage fermenter XOS was seen to increase butyrate production in both 
vessels as compared to fermentation of cornstarch. The increase in butyrate concentrations 
was consistent with an increased level of the C. coccoides group, comprising important 
butyrate producing bacteria [237], in both vessels, but only with a reduced faecal water 
genotoxicity in vessel 1 (pH 5.5). In contrast, the genotoxicity was increased in vessel 2 (pH 
6.8). Microbial changes suggested to contribute to the increase in genotoxicity were the 
reductions in Bifidobacterium spp. and sulphate-reducing bacteria (SRB) observed for vessel 
2. In contrast, an increase in SRB was observed for vessel 1 (decreased genotoxicity), 
suggesting a beneficial effect of SRB relative to protection against protein-induced genetic 
damage. Other microbial changes potentially associated with the reduced genotoxicity in 
vessel 1 were the increase in Lactobacillus spp. and the B. fragilis group, both previously 
shown to be stimulated by XOS [182, Manuscript II]. The increase in these bacterial groups 
may thus indicate a higher level of XOS fermentation in vessel 1 relative to vessel 2, 
potentially reducing the release of genotoxic by-products from protein degradation in vessel 1 
and thus reducing the genotoxic potential of faecal water samples from this vessel.   
In vitro models are associated with some limitations such as the lack of a host immune system 
and the absorptive processes exerted by the gut epithelium [238]. Hence, some of the 
inconsistency observed between the in vitro fermentation study and the in vivo study 
(Manuscript I and II) might be explained by the models used. For example, the lack of 
absorption of SCFAs in the in vitro model may reveal changes in the production of acids that 
would not have been seen in an in vivo model. Concerning the decrease in bifidobacteria seen 
in vitro it should be note that XOS was seen to stimulate bifidobacteria in Manuscript II, as 
also observed in other in vivo studies [142,185,186]. Other contradicting results were the 
increase in the C. coccoides group seen in vitro versus the decrease in this bacterial group 
observed in vivo in faecal samples from mice fed XOS. Thus, even though in vitro modelling 
provides a means of investigating effects related to otherwise inaccessible gut regions in 
humans [238] some inconsistency between results obtained might arise from the models 
chosen. In addition, some of the inconsistency between the in vivo and in vitro studies 
presented in this thesis may also reflect differences in the mouse vs. the human microbiota. 
In conclusion, the experimental studies included in this thesis add to our understanding of 
effects of non-digestible dietary carbohydrates on the composition of the large intestinal 
microbiota and how dietary interventions with such substrates may affect the susceptibility to 
Salmonella infections or the risk of developing colon cancer. The new knowledge gained 
includes (I) a demonstrated reduced resistance of mice to S. Typhimurium infection in 
response to FOS or XOS feeding, (II) the ability of FOS and XOS to change the overall 
composition of the murine faecal microbiota, (III) the ability of XOS to stimulate numbers of 
butyrate producing bacteria (the C. coccoides group) and the production of butyrate in vitro 
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and (IV) an altered human faecal water genotoxicity as a result of XOS fermentation 
demonstrating distinct effects relative to fermentation vessels. 
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